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The regulation of gene expression is one of the most intensely investigated areas 
in all of life sciences. Differential gene expression in multicellular organisms forms 
the foundation of cell-type specificity. Deregulation of the appropriate pattern of 
gene expression has profound effects on cellular function and underlies many 
diseases. Although there are many cellular processes that control gene expression, 
the most direct regulation occurs during transcription. The transcription of protein-
coding genes in eukaryotes is carried out by RNA polymerase II (RNAPII). Until 
recently, the vast majority of studies aimed at elucidating the molecular 
mechanisms of transcription regulation have focused on early stages, such as the 
formation of a transcription initiation complex (pre-initiation) or initiation. For several 
years, transcript elongation has been thought of as the trivial addition of 
ribonucleoside triphosphates to the growing mRNA chain, but this process is 
actually a dynamic and highly regulated stage of the transcription cycle, capable of 
coordinating downstream events. In particular, recent studies have challenged the 
once commonly held view that transcription is predominantly regulated at the level 
of RNA polymerase II (RNAPII) recruitment to the promoter and it is now clear that 
many genes in organisms from flies to men are regulated by reversing early blocks 
to RNAPII elongation (Chao and Price, 2001; Price, 2000). 
 
Promoter escape (or promoter clearance) 
Transcription starts with pre-initiation complex (PIC) assembly at the promoter. The 
PIC includes RNAPII and several general transcription factors (GTFs) (Orphanides 
et al., 1996). After melting of the double stranded DNA, transcription initiation 
occurs upon addition of two initiating nucleotides triphosphates and formation of 
the first phosphodiester bond (Goodrich and Tjian, 1994).  
The first block to elongation occurs after this step: before RNAPII becomes 
engaged into productive transcript elongation, it needs to escape the ties that bind 
it to the promoter (promoter clearance). An important but poorly understood aspect 




rather than merely be embedded in it at the promoter (Thoma, 1991). Therefore the 
PIC must eventually be disassembled: a subset of GTFs remains at the promoter, 
serving as a scaffold for the formation of the next transcription initiation complex 
(Yudkovsky et al., 2000; Zawel et al., 1995). During promoter clearance, RNAPII 
itself must undergo structural and functional maturation in order to break its 
contacts with promoter-sequence elements and to tighten its grip on the nascent 
RNA. 
The main structural change that occurs to RNAPII during early stages of 
transcription is the hyper-phosphorylation of the C-terminal domain (CTD) of its 
largest subunit, Rpb1. RNAPII CTD contains multiple repeats of the heptapeptide 
sequence YSPTSPS, each of which can be phosphorylated. The number of 
repeats increases with genomic complexity: 26 in yeast (Allison et al., 1985), 45 in 
Drosophila (Allison et al., 1988; Zehring et al., 1988), and 52 in mammals (Corden 
et al., 1985). The existence of the hypo- and hyper-phosphorylated forms of 
RNAPII (IIA and IIO, respectively) was first described in the early 1980s (Dahmus, 
1981). Studies using functional assays together with antibodies specific to one or 
the other form of RNAPII demonstrated that RNAPII in the pre-initiation complex 
(PIC) was unphosphorylated (Laybourn and Dahmus, 1989; Lu et al., 1991), 
whereas transcription-competent RNAPII was heavily phosphorylated on its CTD 
(Christmann and Dahmus, 1981); subsequently, Ser2 and Ser5 residues were 
identified as the major modification sites. 
The three kinases that target the RNAPII CTD are the transcriptional cyclin-
dependent kinases Cdk7, Cdk8, and Cdk9 (Prelich, 2002). These enzymes are 
evolutionarily conserved from yeast to mammals, and all are components of protein 
complexes.  
Cdk8 associates with the Srb/Mediator complex and functions in transcriptional 
events prior to elongation (Cho et al., 1998; Maldonado et al., 1996). Cdk7 is a 
subunit of the general transcription factor TFIIH (Orphanides et al., 1996) and 
phosphorylates RNAPII CTD on Ser5 immediately after the formation of the first 
phosphodiester bond of the nascent transcript,  thus regulating RNAPII promoter 
clearance (Akoulitchev et al., 1995; Orphanides and Reinberg, 2002; Rodriguez et 




complex (Zhu et al., 1997) and phosphorylates RNAPII CTD on Ser2 after the 
positioning of the 5’ cap to the mRNA (Cho et al., 2001). 
There are also CTD phosphatase that reverse the status of the CTD. Among them, 
the FCP1 phosphatase targets the CTD of RNAPII (Archambault et al., 1997; 
Archambault et al., 1998; Chambers and Dahmus, 1994) and participates in 
RNAPII recycling (Cho et al., 1999; Mandal et al., 2002). 
 
Promoter-proximal pausing 
Before becoming a fully productive elongation complex, the early elongation 
complex undergoes continued adjustments and this process is often accompanied 
by transcriptional pausing (or stalling) near the promoter. Promoter-proximal 
pausing is a phenomenon whereby RNAPII pauses in the 5’ region of the 
transcription unit and only progresses efficiently into productive elongation upon 
stimulation by appropriate signals. It constitutes the second block to transcription 
elongation and functions as a checkpoint before committing to productive 
elongation.  
The most notable examples of genes that harbor a paused polymerase include the 
heat-shock-inducible genes and the mammalian proto-oncogenes MYC and FOS 
(Lis, 1998); this mechanism, however, is more widely exploited, since it that takes 
place at many genes in eukaryotes (Raschke et al., 1999) and during viral 
transcription (Barboric and Peterlin, 2005). 
Candidate pausing factors were discovered during attempts to reconstitute in vitro 
transcription that displays the same sensitivity to the inhibitor 5,6-dichloro-1-β-D-
ribofuranosylbenzimidazole (DRB) as seen in vivo. DRB sensitivity inducing factor 
(DSIF) and negative elongation factor (NELF) (Wada et al., 1998; Yamaguchi et al., 
1999) were both required for the inhibition of transcription by DRB in vitro and their 
negative effect could be overcome by the action of the protein that was actually 
inhibited by DRB, namely P-TEFb.  
DSIF and NELF, bind to RNAPIIA, the hypo-phosphorylated form of the 
polymerase, that contains Ser5P but not Ser2P (Wada et al., 1998; Yamaguchi et 
al., 1999) and they  cooperate to inhibit the elongation rate of RNAPII by increasing 




The paused RNAPII is then joined by the capping enzyme that interacts with the 
Ser5P CTD and DSIF (Kim et al., 2002; Wada et al., 1998; Wen and Shatkin, 1999) 
and the nascent RNA becomes capped. Following the addition of a cap to the 5’ 
end of the nascent RNA, the negative effect of DSIF and NELF are relieved by the 
action of P-TEFb, which phosphorylates DSIF, NELF and RNAPII CTD on Ser2 
(Cho et al., 2001). Once the transition to productive elongation has taken place, 
NELF leaves the elongation complex while DSIF remains associated and becomes 
a positive factor.  
It is not clear how P-TEFb is recruited to the transcription complexes. P-TEFb may 
be recruited to RNAPII at the promoter, and its kinase activity may be inactive until 
the cap has been added. Indeed, the observation that transcriptional activators can 
interact with P-TEFb suggests that this enzyme may be recruited to the initiation 
complex at the promoter (Barboric et al., 2001; Kanazawa et al., 2000). 
Alternatively, P-TEFb may join the paused RNAPII complex after capping: the 
capping enzyme may assist the recruitment of Cdk9 as in S. pombe, in which the 
Cdk9 ortholog directly binds a subunit of the capping apparatus (Pei et al., 2003).  
In all likelihood, efficient elongation requires that the CTD is kept hyper-
phosphorylated during the entire length of the run, but the precise mechanism of 
action of the kinases responsible, and indeed, the processes leading to CTD de-
phosphorylation are not yet well defined. CTD de-phosphorylation is likely to be a 
continuing occurrence during elongation, as kinase inhibitors such as DRB and H8, 
inhibit elongation both in vivo and in vitro (Chodosh et al., 1989; Marshall and 
Price, 1995; Yankulov et al., 1995; Yankulov et al., 1996), and CTD kinases, such 
as Ctk-1 and P-TEFb, stimulate transcript elongation (Chodosh et al., 1989; Lee 
and Greenleaf, 1997; Marshall and Price, 1995; Yankulov et al., 1995; Yankulov et 
al., 1996). This indicates that the hyper-phosphorylated state of the CTD, acquired 
at the initiation–elongation transition, needs to be maintained, perhaps in order to 





Figure 1. A “Checkpoint” model for the coupling of 5’ pre-mRNA capping and early 
transcription initiation. Adapted from (Orphanides and Reinberg, 2002). 
 
The CTD code 
As transcription elongation proceeds, the RNA transcript is matured by capping 
and splicing, and these events, as well as the termination-coupled processes 
leading to mRNA polyadenylation, all happen co-transcriptionally, that is, coupled 
to the progress of RNAPII along the gene (Kornberg, 2001; Proudfoot et al., 2002). 
It is now established that the RNAPII CTD plays a central role in the ordered 
recruitment of protein factors involved in elongation, as well as in mRNA 
maturation, surveillance, and export (Hirose et al., 1999; Orphanides and Reinberg, 
2002; Proudfoot et al., 2002).  
The Mediator complex binds RNAPII at least partly via the CTD and enhances 




Mediator is absent from elongation complexes containing hyper-phosphorylated 
RNAPII (Pokholok et al., 2002; Svejstrup et al., 1997), thus CTD phosphorylation 
probably induces the disruption of CTD-Mediator interactions, enabling recycling of 
Mediator to a new initiating polymerase (Svejstrup et al., 1997); in all likelihood, 
other RNAPII-GTF interactions are also broken by CTD phosphorylation (Usheva 
et al., 1992). 
While leading to disruption of one set of interactions, CTD phosphorylation might 
concomitantly establish another set. The phosphorylated CTD recruits capping 
enzymes (Cho et al., 1997; Rodriguez et al., 2000; Yue et al., 1997) and the SR 
proteins involved in splicing (Greenleaf, 1993; Kim et al., 1997; Patturajan et al., 
1998).  
Similar to capping and splicing, transcription termination and 3’-end processing 
require factors that associate with the RNAPII CTD. Several components of the 3’-
end processing machinery interact with the Ser2P CTD in vitro (Barilla et al., 2001; 
Licatalosi et al., 2002), and RNAPII has been shown to stimulate 3’-end processing 
(Hirose and Manley, 1998; Proudfoot et al., 2002). Moreover 3’-end processing 
defects were the major alterations resulting from a loss of Ser2 phosphorylation 
(Ahn et al., 2004; Ni et al., 2004). In addition, the Ser2 kinases Ctk1 and Cdk9 
have been shown to be essential for the 3’-end processing in both S.cerevisiae 





Figure 2. The CTD can be modified by phosphorylation, glycosylation, and 





The CTD is a simple repetition of an heptapeptide sequence, so how does such a 
simple sequence interact with so many targets?  A series of different 
phosphorylation and conformation changes generates configurations specific for 
binding of particular factors. In essence, the existence of a “CTD code” has been 
inferred, that specifies the position of RNAPII in the transcription cycle (Buratowski, 
2003). 
The two phosphorylations on Ser5 and Ser2 help distinguish early and late phases 
of transcription. Chromatin Immunoprecipitation (ChIP) data on the fate of Ser5 and 
Ser2 phosphorylation during transcription have indicated that Ser5 phosphorylation 
is high at the promoter, and then decreases towards the 3’-end of the gene, while 
Ser2 phosphorylation increases towards the 3’-end of the gene (Cho et al., 2001; 
Komarnitsky et al., 2000; O'Brien et al., 1994; Schroeder et al., 2000). Thus, it 
appears that CTD phosphorylation at Ser5 correlates with transcription initiation 
and early elongation (promoter clearance), whereas Ser2 phosphorylation is 
associated with RNAP II farther away from the promoter.  
It is important to note that a recent report characterizing the antibodies frequently 
used to distinguish between Ser5 and Ser2 CTD phosphorylation revealed that the 
Ser2-specific antibody  can recognize in some circumstances both the Ser5 and 
Ser2 phosphorylated forms (Jones et al., 2004). Hence it may be necessary to re-
examine some previously published information, although the general trends are 
likely to remain valid.  
In addition to phosphorylation, the CTD code probably also includes cis-trans 
isomerization at two prolines that follow the phosphorylated serines. The proline 
isomerase Pin1/Ess1 acts at prolines preceded by a phosphorylated residue and 
has been involved in mRNA 3’-end formation. It remains to be determined whether 
phosphorylation changes the equilibrium between the cis and trans form of the 
CTD prolines.  
Just considering the possible patterns of phosphorylation and proline 
configurations, sixteen distinct states can be specified within a single CTD repeat. 






P-TEFb (positive transcription elongation factor b) was originally identified based 
on its ability to stimulate DRB-sensitive transcription of long transcripts in vitro 
(Marshall et al., 1996; Marshall and Price, 1992). The heterodimeric P-TEFb 
complex consists of the Cdk9 kinase that associates either with Cyclin T1, Cyclin 
T2a, Cyclin T2b, or Cyclin K (Peng et al., 1998; Peng et al., 1998). The elongation 
activity of P-TEFb is dependent on its kinase activity on RNAPII CTD and 
DSIF/NELF during  promoter clearance (Price, 2000). P-TEFb targets specifically 
Ser2 of the CTD, as demonstrated by RNA interference studies in C. elegans 
(Shim et al., 2002) and by exploiting the highly specific P-TEFb inhibitor flavopiridol 
(Ni et al., 2004). 
Upon heat shock, P-TEFb is rapidly recruited to transcriptionally active loci on 
Drosophila polytene chromosomes and frequently co-localizes with the promoter-
paused hypo-phosphorylated form of RNAPII (Lis et al., 2000). These results 
suggest that P-TEFb is recruited to facilitate productive elongation upon RNAPII 
pausing. Additional experiments revealed that P-TEFb appeared to track along with 
RNAPII during elongation with similar kinetics (Andrulis et al., 2000; Boehm et al., 
2003). Therefore P-TEFb seems to act not only during promoter escape but also 
during transcriptional elongation. 
 
The P-TEFb core complex 
Cdk9 is a 43 kDa protein that has been originally identified during a cDNA 
screening aimed at isolating novel regulators of the mammalian cell cycle (Grana et 
al., 1994). As no cyclin partner or cell cycle function was demonstrated at that time, 
Cdk9 was temporarily designated PITALRE for its PSTAIRE-like sequence, a 
conserved motif found in CDC2 and related kinases (Pines, 1994). The cellular 
function of Cdk9 remained unknown until the Drosophila homologue of human 
PITALRE, Cdk9, was identified as the small subunit of the P-TEFb factor by 
Marshall and Price (Marshall and Price, 1995).  
Recently, a novel isoform of Cdk9 has been identified, which is transcribed from an 




resulting 55 kDa  Cdk9 isoform interacts with Cyclin T1 and 7SK and is able to 
phosphorylate RNAPII CTD like the 43 kDa isoform.  
The two isoforms of Cdk9 have a differential expression.  Cdk955 is the minor form 
of Cdk9 in HeLa and NIH/3T3 cells, comprising less than 20% of total Cdk9. 
However, the relative amount of the two forms is altered in cultured human 
macrophages, with Cdk955 predominating. Interestingly, this ratio is altered upon 
LPS (lipopolysaccharide) treatment or HIV-1 infection of the macrophages, leading 
to a change in the relative amounts of the two forms with Cdk942 becoming the 
major form (Shore et al., 2003). 
Western analysis of murine tissues has shown that the relative abundance of the 
two forms of Cdk9 varies across different tissues, with liver having more Cdk955 
than Cdk942. During adaptation of primary rat hepatocytes to culture, the ratio of 
the two forms of Cdk9 changed. Initially, Cdk955 was the predominant form, but as 
the cells began to enter the cell cycle Cdk942 became the major form. This 
suggests that Cdk942 and Cdk955 may have specific functions in dividing and 
nondividing cells respectively, or that dividing cells have a higher need for P-TEFb 
and that induction of the Cdk942 promoter provides the extra Cdk9 required (Shore 
et al., 2005).Moreover the two isoforms have different localization: epitope tagged 
transiently expressed Cdk942 localized diffusely in the nucleoplasm, while Cdk955 
accumulated in nucleolus (Liu and Herrmann, 2005). 
Cdk9 has two homologs in yeast, Ctk1 and Bur1 (Yao and Prelich, 2002). The two 
yeast kinases likely contain distinct functional activities and may have different 
targets in vivo. Whereas Bur1 is essential for cell viability, Ctk1 is not (Lee and 
Greenleaf, 1991; Patturajan et al., 1999; Prelich and Winston, 1993; Yao et al., 
2000). Even though Bur1 phosphorylates the RNAPII CTD, genetically interacts 
with CTD truncations, and co-localizes with elongating RNAPII, mutations in the 
Bur1 gene do not appear to affect either Ser2 or Ser5 phosphorylation in the cells 
(Keogh et al., 2003; Murray et al., 2001).  
Ctk1 is responsible for elongation-associated Ser2 phosphorylation of the CTD and 
is localized to the coding regions of genes (Cho et al., 2001; Patturajan et al., 
1999). Deletion of Ctk1 results in loss of histone H3-K36 methylation and Set2 




Ctk1 in the regulation of transcript elongation. However, the fact that Ctk1 is not 
essential suggests that other kinases, likely Bur1, can compensate for its 
deficiency.  
The Cyclin T1 regulatory subunit of Cdk9 was independently identified by the 
groups of Katherine Jones and David Price using different strategies (Peng et al., 
1998; Wei et al., 1998). Subsequently, three T-type cyclins were identified in 
human cells and were named Cyclins T1, T2a and T2b (T-type cyclins; (Peng et 
al., 1998). Cyclins T2a and T2b are splice variants of a primary transcript. The two 
cyclins share the first 642 amino acids, but Cyclin T2b contains a larger C-terminal 
domain. The three T-type cyclins share a highly conserved N-terminus containing 
an 81% identical cyclin box. However, the C-terminus is much less conserved 
(46% identity) (Peng et al., 1998). In addition to the N-terminal cyclin domain, 
Cyclin T1 contains a putative coiled-coil motif, a His-rich motif and a carboxy-
terminal PEST sequence (Wei et al., 1998). PEST sequences have been 
previously identified in proteins with high turnover rates, including G1 cyclins, and 
appear to regulate protein turnover by ubiquitin-dependent proteolysis (Rechsteiner 
and Rogers, 1996). However, the role of the PEST sequence present in Cyclin T1 
is not well understood. 
A more distantly related cyclin, Cyclin K, has also been shown to both interact and 
form an active complex with Cdk9 (Fu et al., 1999). Interestingly, in contrast to T-
type cyclin/Cdk9 complexes, Cyclin K/Cdk9 can only activate transcription when 
tethered to RNA but not DNA. Cyclin K lacks an essential His-rich region in its 
carboxy terminus that, in Cyclin T1, helps recognizing the RNAPII CTD (Lin et al., 
2002).  
 
P-TEFb regulatory partners 
In human HeLa cells, more than half of the P-TEFb heterodimer is associated with 
large ribonucleoprotein (RNP) complexes which also contain the 7SK small nuclear 
RNA (Nguyen et al., 2001; Yang et al., 2001)  and the HEXIM1 or HEXIM2 protein 
(Byers et al., 2005; Michels et al., 2003; Yik et al., 2003; Yik et al., 2005). Actually 
the large complex seems to be formed by one 7SK molecule, multimers  of 




Association of P-TEFb with 7SK/HEXIM1 is specific and reversible. Inhibition of 
cellular transcription by chemical agents or ultraviolet irradiation triggers the 
disruption of the P-TEFb/7SK complex (Nguyen et al., 2001; Yang et al., 2001).  
In contrast to its free form, the 7SK/HEXIM-associated fraction of P-TEFb shows 
little kinase activity, indicating that the 7SK snRNA, in collaboration with HEXIM1, 
functions as an inhibitory factor of P-TEFb. In HeLa cells, the overexpression of 
HEXIM1 inhibits the activity of a variety of reporter promoters whereas the siRNA-
mediated knockdown of HEXIM1 expression results in transcriptional activation 
(Fraldi et al., 2005; Yik et al., 2003). 
Likewise, the depletion of 7SK snRNA increases the CTD kinase activity of P-TEFb 
and stimulates transcription from RNAPII specific promoters, including the HIV-1 
long terminal repeat (Nguyen et al., 2001; Yang et al., 2001). Thus, it is 
conceivable that certain cellular processes marked by an increase in global 
transcription are modulated by changes in the availability of free P-TEFb. An 
example of such a global process leading to an increase in the synthesis of total 
RNA is illustrated by cardiac muscle hypertrophy, which is due to increased cardiac 
workload or defective mechanical performance (Sano et al., 2002). Hypertrophic 
signals dissociate the 7SK snRNA from T-type cyclins/Cdk9 complexes, leading to 
an increase in Cdk9 activity that results in hyper-phosphorylation of the CTD of 
RNAPII (Sano et al., 2002).  
Recently two groups have identified a new component of the P-TEFb active 
complex, the Brd4 protein. Brd4 is a mammalian bromodomain protein that binds to 
acetylated chromatin and interacts with P-TEFb (specifically with Cyclin T1) 
through its bromodomain (Jang et al., 2005). It interacts with active P-TEFb free of 
7SK/HEXIM  and stimulates its kinase and transcriptional activity (Jang et al., 2005; 
Yang et al., 2005). Moreover chromatin immunoprecipitation (ChIP) assays  
revealed that the recruitment of P-TEFb to promoters was dependent on Brd4, 
which contacts DNA through acetylated histones as well as through the Mediator 




P-TEFb and  HIV-1 transcription 
In mammalian cells, the role of P-TEFb has been initially highlighted by the 
association of Cyclin T1 with the human immunodeficiency virus type 1 (HIV-1) Tat 
transactivator (Mancebo et al., 1997; Wei et al., 1998; Zhu et al., 1997).  
The HIV-1 long terminal repeat  (LTR) promoter depends on P-TEFb activity more 
than normal cellular promoters, since activation of that promoter by the viral 
transactivator Tat is blocked by concentrations of P-TEFb inhibitors that do not 
affect regular cellular transcription (Chao et al., 2000; Chao and Price, 2001; Flores 
et al., 1999).  
Tat is unique among transcriptional activators in eukaryotic cells in that it functions 
via RNA rather than DNA promoter elements. It binds the transactivation response 
element (TAR) that forms a stable RNA stem loop at the 5′ end of all viral 
transcripts. Thus, Tat requires minimally the transcription of TAR before it can 
stimulate HIV transcription from the long terminal repeat (LTR). Indeed, in the 
absence of Tat, RNAPII clears the HIV LTR successfully but soon arrests, yielding 
predominantly short viral transcripts (Kao et al., 1987). Tat binds the 5′ bulge in 
TAR via its arginine-rich motif from positions 49 to 57. However, this binding is not 
sufficient for Tat's function in vivo. The N-terminal core and cysteine-rich regions, 
which form the activation domain of the protein, lie adjacent to the arginine-rich 
motif. This activation domain binds Cyclin T1 (Wei et al., 1998). As a consequence, 
a tripartite complex is formed between Tat, Cyclin T1 and TAR at the 5’ end of 
each viral mRNA.  The formation of the P-TEFb-TAR-Tat complex is an essential 
step towards the assembly of the processive RNAPII machinery at the LTR 
promoter (Bieniasz et al., 1998; Fujinaga et al., 1998; Garber et al., 1998; Zhou et 
al., 1998).  
The assembly and disassembly of the complex between P-TEFb, Tat, and TAR is a 
regulated process in vivo. Whereas the phosphorylation of Cdk9 (Garber et al., 
2000) and the P/CAF-mediated acetylation of the lysine 28 of Tat strengthens this 
complex, the p300-mediated acetylation of the lysine 50 of Tat weakens it (Kiernan 






Figure 3. Early phases of HIV-1 transcription. Adapted from (Barboric and Peterlin, 
2005). 
 
Interestingly, the HEXIM1 protein binds the same region at the N-terminus of Cyclin 
T1 that is responsible for Tat binding  (Michels et al., 2003). As a matter of fact,  
GST pull-down experiments and size exclusion chromatography reveal a mutually 
exclusive binding of the two effectors to Cyclin T1, suggesting a model where HIV-
1 Tat competes with HEXIM1 for CyclinT1 binding (Schulte et al., 2005). 
Furthermore, the 7SK-binding motif in HEXIM1 contains clusters of positively 
charged residues reminiscent of the arginine-rich RNA-binding motif found in a 
wide variety of proteins. Part of it is highly homologous to the TAR RNA-binding 
motif of Tat. A similar RNA-protein recognition mechanism may regulate the 
formation of both the Tat-TAR-P-TEFb and the HEXIM1-7SK-P-TEFb ternary 
complexes, which may help convert the inactive HEXIM1/7SK-bound P-TEFb into 
an active complex for Tat-activated and TAR-dependent HIV-1 transcription 
(Michels et al., 2004; Yik et al., 2004).  Therefore it has been speculated that the 
TAR RNA/Tat lentiviral system has evolved to subvert the cellular 7SK RNA 
/HEXIM1 system.  
 
P-TEFb and transcription 
Although Tat was the first activator known to recruit P-TEFb to initiating RNAPII, 




transactivator, HTLV Tax (Zhou et al., 2006), and mammalian activators such as 
the androgen receptor (Lee et al., 2001), c-Myc (Eberhardy and Farnham, 2001), 
the class II transactivator (CIITA) (Kanazawa et al., 2000), myoblast determination 
protein (MyoD) (Giacinti et al., 2006), and nuclear factor κB (NF-κB) (Barboric et 
al., 2001). These forms of recruitment of P-TEFb are specific and tailored to 
individual transcription units. Nevertheless P-TEFb involvement in transcription 
appears to be a more general feature. In fact, in C. elegans, genetic inactivation of 
Cdk9 or Cyclin T1 and Cyclin T2 resulted in the inhibition of all RNAPII transcription 
(Shim et al., 2002). Although no murine knockouts of subunits of P-TEFb have 
been reported, DRB and flavopiridol, two ATP analogs that inhibit the kinase 
activity of Cdk9, can inhibit nearly all transcription by RNAPII in human cells (Chao 
and Price, 2001). Therefore there should also be a general mechanism for bringing 
P-TEFb to RNAPII. The association of P-TEFb with the Brd4 protein, which 
associates with the Mediator and binds acetylated histones, (Jang et al., 2005; 
Yang et al., 2005), might provide one possible general tethering system. 
In any case, these observations do not rule out the possibility that specific P-TEFb 
complexes could be rate-limiting for the expression of a subset of genes under 
certain cellular instances.  
 





P-TEFb and cellular differentiation  
In contrast to Cdks with known cell cycle regulatory functions, the Cdk9-associated 
kinase activity is fairly constant throughout both the cell cycle and during cell cycle 
entry from a quiescent state (Garriga et al., 2003; Grana et al., 1994), but it  
changes during cell differentiation (De Falco et al., 2005; Foskett et al., 2001; Sano 
et al., 2002; Simone et al., 2002) and viral infection (Bark-Jones et al., 2005; Liou 
et al., 2004; Tamrakar et al., 2005; Zhou et al., 2000). 
The discovery of Cdk9 as the catalytic subunit of the Tat-Associated Kinase 
(Herrmann and Rice, 1993; Herrmann and Rice, 1995), the activity of which 
appeared to be dramatically upregulated during T-cell activation (Yang et al., 
1997), prompted the examination of the regulation of P-TEFb expression in cells 
that are target for HIV-1 infection. 
Cyclin T1 protein levels have been shown to increase following activation of 
peripheral blood lymphocytes (PBLs) and the upregulation of Cyclin T1 to correlate 
with hyper-phosphorylation of RNAPII and increased HIV  replication in these cells  
(Garriga et al., 1998; Ghose et al., 2001; Herrmann et al., 1998; Marshall et al., 
2005). 
Cdk955 is expressed at relatively high levels in resting lymphocytes and is not 
regulated by activation, while Cdk942 is expressed at low levels in resting 
lymphocytes and seems to be upregulated by activation (Liu and Herrmann, 2005) 
In human monocytes and macrophages, Rice and colleagues have observed 
complex patterns of P-TEFb regulation. CyclinT1 mRNA levels are high but little 
protein expression can be observed in monocytes freshly isolated from healthy 
blood donors (Liou et al., 2002). When monocytes are instead cultured under 
conditions that induce macrophage differentiation, CyclinT1 protein expression is 
induced to high levels within one or two days. In contrast, Cdk9 protein levels are 
generally high in freshly isolated monocytes and are not strongly upregulated 
during differentiation. However, after approximately seven to ten days of 
macrophage differentiation in culture, CyclinT1 protein expression is shut-off by 
proteasome-mediated proteolysis (Liou et al., 2004). Macrophages activators such 
as lipopolysaccharide or other pathogen-associated molecular patterns (PAMPs) 




CyclinT1 is a component of the innate immune response (Liou et al., 2004). 
Interestingly, HIV infection can also induce CyclinT1 expression in the late 
differentiated-macrophages (Liou et al., 2004). In this respect, however, it should 
be mentioned that  these findings have been challenged by a study that reported 
no significative differences in CyclinT1 expression levels between  unstimulated 
and stimulated primary lymphocytes (Martin-Serrano et al., 2002).  
Besides cells that are target for HIV infection, there are other examples of  
differentiating cells in which  P-TEFb activity appears to be regulated.  
In the mouse, the kinase activity and protein expression of Cdk9 are highest in 
terminally differentiated tissues such as the muscle and brain (Bagella et al., 1998). 
In keeping with this notion, C2C12 cells induced to differentiate along muscle 
lineages peaked in Cdk9 kinase activity during differentiation. Overproduction of 
Cdk9 and of its associated cyclin (Cyclin T2a) stimulates myogenic differentiation in 
both MyoD-converted fibroblasts and C2C12 muscle cells. Conversely, inhibition of 
Cdk9 activity by a dominant negative form (Cdk9-dn) represses the myogenic 
program (Simone et al., 2002). Furthermore, Cdk9, Cyclin T2a and MyoD can be 
detected in a multimeric complex on promoters where Cdk9 strengthens MyoD-
dependent transcription (Giacinti et al., 2006; Simone et al., 2002) 
Cardiac Cdk9 kinase activity declines during normal cardiac maturation but is 
reactivated by hypertrophic signals. In these cases little or no change occurs in the 
levels of the kinase or of its activator, CyclinT. Instead, Cdk9 activation involves the 
dissociation of the inhibitor 7SK small nuclear RNA (Sano et al., 2002). 
In contrast to this system, the Rice’s group has observed that 7SK RNA and 
HEXIM1 protein expression, and the association of 7SK with P-TEFb, are induced 
upon activation of quiescent lymphocytes, parallel, however, to the increase of 
Cdk9 kinase activity (Haaland et al., 2003; Haaland et al., 2005). On the other 
hand, increased HEXIM1 expression has been shown to correlate with inhibition of 
P-TEFb activity during erythroleukemia cell differentiation (Turano et al., 2006).   
The Cdk9/CyclinT1 complex seems to be also required for neuron differentiation 
induced by retinoic acid, since the expression level of the complex increases during 
differentiation. In addition, in samples of neuroblastoma and PNET (Primary 




state of the tumor  (De Falco et al., 2005). HEXIM1 expression appears to be 
regulated during neuroblastoma cell differentiation as well (Turano et al., 2006). 
Finally P-TEFb has been found to participate in the process of adipogenesis. Cdk9, 
as well as CyclinT1 and CyclinT2, show differences in nuclear localization at 
distinct stages of adipogenesis. Overexpression of Cdk9 increases the adipogenic 
potential of 3T3-L1 cells, whereas the inhibition of Cdk9 by specific Cdk inhibitors 
and by a dominant-negative Cdk9 mutant impairs adipogenesis. The positive 
effects of Cdk9 on the differentiation of 3T3-L1 cells are mediated by a direct 
interaction with, and by the phosphorylation of, peroxisome proliferator-activated 
receptor gamma (PPARgamma), which is the master regulator of this process, on 
the promoter of PPARgamma target genes. PPARgamma-Cdk9 interaction results 
in increased transcriptional activity of PPARgamma and therefore increased 
adipogenesis (Iankova et al., 2006). 
Not only cellular differentiation but also viral infection can modify P-TEFb activity. 
HIV-1 infection induces CyclinT1 expression (Liou et al., 2004), while HCMV 
infection increases Cdk7 and Cdk9 protein levels and kinase activity (Tamrakar et 
al., 2005). Besides regulating the overall level of kinase activity, cell infection by 
different viruses may also change the substrate specificity of Cdk9: in presence of 
HIV Tat or EBV EBNA2, Cdk9 phosphorylates RNAPII CTD on both Ser2 and Ser5 
(Bark-Jones et al., 2005; Zhou et al., 2000). 
 
Cdk9 post-translational modifications  
The stability and activity of P-TEFb are regulated by multiple mechanisms. 
The maturation of active CyclinT1/Cdk9 complexes is mediated by a chaperone 
pathway that sequentially transfers newly synthesized Cdk9 from HSP70 to 
HSP90/Cdc37 and finally to Cyclin T1 (O'Keeffe et al., 2000). A factor in this 
pathway appears to be rate-limiting for the stabilization of Cdk9, since ectopic 
expression of an HA-tagged version of Cdk9 leads to downregulation of 
endogenous Cdk9 (Garriga et al., 2003; Garriga et al., 1996). This downregulation 
of endogenous Cdk9 when Cdk9 is ectopically overexpressed is due to an 




et al., 2003; O'Keeffe et al., 2000), suggesting that saturation of the pathway 
mediating stabilization of Cdk9 induces the degradation of free Cdk9. 
Kiernan et al. hypothesized that Cdk9 stability could be regulated by an ubiquitin-
proteasome system. In fact, they found that Cdk9 is modified by ubiquitin in an 
unusual way: CyclinT1 recruits the ubiquitin ligase through its PEST domain, but 
then it is Cdk9 that is ubiquitinated and degraded by the proteasome (Kiernan et 
al., 2001). While subsequent work has questioned this conclusion  (Garriga et al., 
2003), it is commonly accepted that Cdk9 activity can be modulated by 
ubiquitination. As a matter of fact, Barboric et al. have demonstrated that 
ubiquitination of Cdk9 by Skp2 facilitates optimal Tat transactivation because it 
strengthens the formation of the ternary complex between P-TEFb, Tat and TAR 
(Barboric et al., 2005). 
Another important post-translational modification of P-TEFb is phosphorylation. 
Cdk9 can be phosphorylated on both serine and threonine residues. In particular, 
like all the other Cdks, it must be phosphorylated on Thr 186 of the T-loop for the 
catalytic pocket to become correctly folded (Ramanathan et al., 1999). Other sites 
of Cdk9 phosphorylation lie within the C-terminus of the protein and can be 
modified by Cdk9 itself or by other protein kinases such as PKA (Garber et al., 
2000). 
Evidence has been provided that Cdk9 autophosphorylation represents an 
important step in binding its cyclin partner and forming  a stable interaction with the 
HIV-1 Tat/TAR complex (Fong and Zhou, 2000; Garber et al., 2000). Cdk9 
phosphorylation is regulated during HIV transcription: in fact TFIIH in the pre-
initiation complex inhibits Cdk9 phosphorylation, whereas Cdk9 is phosphorylated 
and active during transcription elongation when TFIIH is absent from the 
transcription complex (Zhou et al., 2001). 
 
Subcellular localization of P-TEFb  
Transcriptional regulation in mammalian cells is a highly dynamic process, 
requiring temporal and spatial coordination of functional protein complex assembly 
(Carmo-Fonseca, 2002; Stein et al., 2000). In addition, transcription overlaps 




2000). For these reasons, several of the factors participating in these events are 
found localized in specific subnuclear compartments; among them, CyclinT1 and 
Cdk9 co-localize in the non-nucleolar nucleoplasm with an evident speckled pattern 
indicative of distribution within compartments (Herrmann and Mancini, 2001).  
In particular, CyclinT1 is exclusively present in nuclear speckled structures while 
Cdk9, albeit mainly nuclear, can also be visualized in the cytoplasm where it is 
actively exported from the nucleus through a leptomycin B-sensitive pathway. 
Interestingly, enforced expression of CyclinT1 enhances nuclear localization of 
Cdk9 and this effect requires the catalytic activity of the kinase (Napolitano et al., 
2002; Napolitano et al., 2003). Cdk9 localization also depends on the differentiation 
status of the cell: in fact, Cdk9 undergoes a change in subcellular localization from 
nucleus to cytoplasm during in vitro-induced myogenesis (MacLachlan et al., 
1998).  
The subnuclear foci in which CyclinT1 resides appear juxtaposed, although not 
exactly coincident, with nuclear speckles, while they co-localize with promyelocytic 
leukaemia (PML) bodies, either upon overexpression of PML or, at least for a 
subset of them, at the levels of expression of the endogenous proteins. 
Localization of CyclinT1 into PML nuclear bodies depends on the physical 
interaction between the two proteins. In fact, CyclinT1 specifically binds PML not 
only in in vitro binding and co-immunoprecipitations experiments, but also in 
fluorescence resonance energy transfer (FRET) experiments that (as explained in 
chapter 5) indicate a direct interaction between the two proteins. Accordingly, 
CyclinT1 deletion mutants unable to associate with PML are also less prone than 
the wild-type protein to form nuclear foci in vivo. Most notably, human CyclinT1 has 
a diffuse localization in the nucleoplasm of fibroblasts derived from PML-knockout 
mice (Marcello et al., 2003).    
The overexpression of Tat, which specifically binds CyclinT1 in FRET experiments, 
determines the recruitment of CyclinT1 outside the Cyclin T1 bodies and promotes 
HIV-1 transcriptional activation (Marcello et al., 2001), whereas CyclinT1 or PML 
overexpression forces CyclinT1 in nuclear bodies and correlates with an inhibition 




Together, these observations favor a model by which nuclear bodies modulate the 
activity of the HIV promoter by coordinating the availability of several factors that 
act in concert and are transiently part of the same complex assembled onto the 
LTR, including P-TEFb, p300/CBP, RNAPII and PML itself. Forced expression of 
PML or of other factors regulated by nuclear bodies such as CyclinT1 or PML  
might shift this dynamic equilibrium toward the formation of larger bodies that do 
not participate in transcription. In contrast, the expression of Tat might recruit these 
factors outside nuclear bodies in a region of nucleoplasm favorable for 
transcription. This model, which is schematically depicted in Figure 5, implies that 
nuclear body proteins shuttle in and out of these domains (Boisvert et al., 2001; 
Phair and Misteli, 2000), and is in agreement with the notion that transcription itself 










The mammalian nucleus is a complex organelle organized into chromatin territories 
and discrete nuclear compartments or bodies. One of these is the promyelocytic 
leukemia (PML) body, also known as the PML oncogenic domain (POD), nuclear 
domain 10 (ND 10) or Kremer (Kr) body. There are approximately 5-30 bodies 
observed per nucleus, ranging in size from ~0.2 to 1 μm (Melnick and Licht, 1999). 
The major structural component of the PML bodies is the PML protein (Dyck et al., 
1994; Koken et al., 1994; Weis et al., 1994). 
The importance of PML bodies in cell differentiation and cell growth was first 
indicated in studies of promyelocytes from patients suffering from acute 
promyelocytic leukemia (APL). APL is a common form of acute myeloid leukemia 
(AML) that can be morphologically characterized by a distinct blockage of myeloid 
differentiation and accumulation of immature promyelocytes in patient bone marrow 
and peripheral blood (Warrell et al., 1993). In 99% of APL cases, a fusion of the 
PML protein and the retinoic acid receptor a (RARa) occurs as a result of the 
chromosomal translocation t(15:17) leading to the production of a PML-RARa 
chimeric protein (de The et al., 1991; Goddard et al., 1991; Kakizuka et al., 1991). 
Through its ability to heterodimerize with PML and RXR, PML-RARa interferes with 
both the PML and RAR/RXR-RA pathways, thus acting as a double dominant 
negative oncogenic product (Dyck et al., 1994; Kastner et al., 1992). 
The role of PML in cell growth and tumorigenesis has been further characterized by 
overexpression and knock out of the PML protein. Stable overexpression of PML 
significantly reduced the growth rate of  HeLa cells lengthening the G1 phase of 
cell cycle (Mu et al., 1997); in contrast,  PML-/- MEFs grew faster than PML+/+ MEFs 
(Wang et al., 1998). These findings  demonstrate that PML can function in vivo as 
a negative growth regulator. Furthermore, PML-/- mice are highly susceptible to 
develop tumors in several in vivo models of physical or chemical induced 
carcinogenesis (Wang et al., 1998), thus indicating that PML can act as a tumor 





Notwithstanding these observations, the following considerations should also be 
taken into account in an assessment of PML nuclear bodies function. First, the 
expression of the PML gene is not required for viability, since PML-/- mice develop, 
in essence, normally (Wang et al., 1998). Second, the PML gene is not 
evolutionarily conserved among eukaryotes, being absent in Drosophila 
melanogaster, Saccharomyces cerevisiae, and Arabidopsis thaliana (Borden, 
2002). Third, unlike other nuclear organelles, there appears to be no PML bodies in 
Xenopus laevis.  
 
PML protein   
The PML protein contains at its N-terminus several important functional domains 
which collectively form the RBCC  or TRIM motif (Jensen et al., 2001). This motif is 
characterized by the presence of a zinc-binding domain that includes the RING 
finger motif followed by two additional zinc fingers (B-boxes) and an a-helical 
coiled-coil motif. The RING finger is a specialized type of zinc finger that is found in 
factors involved in transcription, tumor suppression and genomic stability and that 
may confer E3 ubiquitin-protein ligase activity (Jackson et al., 2000). RING and B-
box motifs are thought to be involved in protein interactions and do not appear to 
bind nucleic acid directly (Borden, 2000). The helical coiled-coil region consists of 
eight heptad repeats (Kastner et al., 1992) and is responsible for multimerization of 
PML (Kastner et al., 1992; Le et al., 1996) as well as its heterodimerization with 
PML-RARa (Grignani et al., 1996; Perez et al., 1993). 
Alternative splicing generates seven major isoforms of PML, which all share the N-
terminal region motif but differ in their C-terminal portions and subcellular 
distribution (Jensen et al., 2001). The majority of PML protein forms nuclear bodies 
(Melnick and Licht, 1999); however, there is some PML located in cytoplasmic 
bodies and a soluble component in the nucleus (Flenghi et al., 1995; Melnick and 
Licht, 1999). A partial cytoplasmic localization is a feature shared even by the PML 
isoforms that are predominantly nuclear (Flenghi et al., 1995; Melnick and Licht, 
1999). 
Post translational modifications of PML regulate PML bodies formation. In 




protein localization within PML nuclear bodies (Eskiw et al., 2003; Maul et al., 
2000; Zhong et al., 2000). For example, although SUMO-1 modification of the PML 
protein is not required for the formation of PML aggregates, the accumulation of 
many other PML nuclear body associated proteins within these structures appears 
to require the sumoylation of PML (Zhong et al., 2000). 
Although the PML protein is the only essential protein for PML body formation 
(Dyck et al., 1994), many other proteins localize to these structures. Up to date 
over 77 proteins are known to localize to this compartment (see the Nuclear 
Protein Database http://npd.hgu.mrc.ac.uk/) (Dellaire et al., 2003), implicating 
these structures in virtually every nuclear activity, including transcription (reviewed 
by (Zhong et al., 2000)), DNA repair (reviewed by (Dellaire and Bazett-Jones, 
2004)), apoptosis (reviewed by (Takahashi et al., 2004)), tumor suppression 
(reviewed by (Salomoni and Pandolfi, 2002)), proteolysis (Lallemand-Breitenbach 
et al., 2001), and the antiviral response (reviewed by (Everett, 2006; Regad and 
Chelbi-Alix, 2001)). 
 
Figure 6. Functions of proteins that localize at PML NBs  or associate with PML 




PML bodies and transcription 
PML has been touted as both a transcriptional activator and repressor. Although 
PML itself does not exhibit DNA binding activity, it can regulate transcription 
through interaction with various transcription factors/cofactors (reviewed in (Zhong 
et al., 2000)).  
PML shows intrinsic repression activity when tethered to a promoter through fusion 
with the Gal4 DNA binding domain (Ahn et al., 1998; Vallian et al., 1997). 
Consistent with this repression activity, overexpression of PML led to inhibition of 
various promoters, including the MDR and EGF-receptor (EGF-R) promoters (Mu 
et al., 1994). In particular for the EGF-R promoter, the mechanism of repression 
was attributed to the PML-dependent disruption of the Sp1-DNA interaction (Vallian 
et al., 1998). PML was also reported to directly interact with the non-
phosphorylated form of Rb and to abrogate the enhancing effect of Rb on 
glucocorticoid receptor-mediated transactivation (Alcalay et al., 1998). Moreover, 
PML has been shown to interact with histone deacetylases (Wu et al., 2001) and 
other co-repressors (c-Ski, N-CoR, and mSin3A) (Khan et al., 2001). 
On the other hand, several lines of evidence suggest that PML can also act as a 
transcription co-activator. PML has been shown to upregulate the transcription of 
genes related to the major histocompatibility complex (Zheng et al., 1998), GATA-2 
(Tsuzuki et al., 2000), AP-1 (Vallian et al., 1998). The positive effect of PML on 
transcription can be partially explained by the fact that it can recruit transcriptional 
co-activators such as CBP and p300 histone acetyltransferases (Doucas et al., 
1999; LaMorte et al., 1998; von Mikecz et al., 2000). In particular for p53 mediated 
transcription, PML is required for the appropriate formation of certain  p53 post-
translational modifications (phosphorylation, acetylation, sumoylation) that 
potentiate its activity (Fogal et al., 2000; Guo et al., 2000; Pearson et al., 2000). At 
the same time, it can bind and inactivate the negative p53 regulator, Mdm2, thus 
protecting p53 from Mdm2-mediated degradation (Kurki et al., 2003; Louria-Hayon 
et al., 2003; Wei et al., 2003).  
Recently, the contribution to transcription of the PML nuclear body itself (and not 
only of the PML protein) has been addressed by artificially tethering reporter 




body environment has been shown to modulate the expression of the reporter 
gene in a promoter-dependent manner (the SV40 promoter was repressed, the 
CMV promoter was activated and a minimal eukaryotic promoter was not affected). 
 
PML bodies and chromatin 
The structure of PML nuclear bodies has been extensively studied using both the 
light and electron microscope to examine their protein composition and 
ultrastructure (Boisvert et al., 2000; Eskiw et al., 2003; Grande et al., 1996; Ishov et 
al., 1999). The bodies are spherical or ring-shaped (Boisvert et al., 2000; Eskiw et 
al., 2003) and often appear as spheroid shells of proteins, with little protein mass at 
their core (Boisvert et al., 2000). Like many nuclear bodies, PML nuclear bodies 
reside in the interchromatin domain (ICD) space (Boisvert et al., 2000).   
While LaMorte et al. reported the existence of nascent RNAPII transcripts within 
this compartment (LaMorte et al., 1998), subsequent analysis demonstrated that 
the core of PML nuclear body is a dense protein-based structure which does not 
contain detectable nucleic acid (Boisvert et al., 2000). Although neither chromatin 
nor RNA are found within the central core of these bodies, newly synthesized RNA 
is associated with their periphery (Boisvert et al., 2000) and both proteins and 
chromatin-like fibers appear to connect the bodies via multiple contacts to the 
surrounding chromatin (Eskiw et al., 2004; Eskiw et al., 2003). These contacts with 
chromatin at the periphery  of the PML nuclear bodies seem to be partly 
responsible for the positional stability over long time intervals during interphase 
(Eskiw et al., 2004; Eskiw et al., 2003).  
The integrity and stability of PML bodies are lost when chromatin is disrupted by 
stress, transcriptional repression or early apoptotic events. Under such conditions, 
PML bodies become mobile (Eskiw et al., 2004; Eskiw et al., 2003; Maul et al., 
1995; Nefkens et al., 2003). Contacts between chromatin and PML bodies could 
have a more profound role  than just the maintenance of their positional stability. 
One hypothesis is that the disruption of PML bodies might directly affect the 
availability of PML body-associated proteins within the nucleus leading to the 




with chromatin also brings together specific gene loci regulated by PML body-
associated proteins.  
 
Figure 7. Ultrastructure of PML nuclear bodies (Dellaire and Bazett-Jones, 2004). 
(A) An electron micrograph of a PML NB is shown by electron spectroscopic 
imaging (ESI). Nucleic acid is visualized in the net phosphorous image (P) and 
both nucleic acid and protein in the net nitrogen image (N). Overlay of the two 
images produces an image where protein-rich structures, such as the PML NB, 
appear green and structures with intermediate protein and nitrogen content, such 
as chromatin and ribonucleoprotein (RNP) complexes, appear yellow. In the 
segmented panel, the ratio of nitrogen and phosphorous is used to segment the 
image into chromatin (red), RNP (blue) and the PML body (green). The PML body 
has a ring-like appearance with a hole at the centre of the PML NB. In addition, a 
finger-like projection from the top of the body can be seen. The PML NB is in 
contact with the surrounding chromatin at several locations (small arrows). (B) A 




through the three-dimensional volume of the PML NB, along the plane shown in 
the back panel of B (white line), is shown.  
 
Many examples of the non-random association of PML nuclear bodies in 
mammalian cells with specific chromosomal loci or chromatin have been reported, 
which include TP53 (Sun et al., 2003) and the MHC gene cluster (Shiels et al., 
2001). Wang et al. have extended the analysis to multiple gene-rich and gene-poor 
regions on other chromosomes in order to determine whether there is a spatial 
organization of PML bodies relative to particular regions of the genome. These 
authors found that PML bodies associate with genomic regions of high 
transcriptional activity, which is a function of both the gene density and the 
proportion of genes that are active. Single genes that are highly expressed do not 
show significant associations with PML bodies alone. The organization of PML 
bodies in relation to transcriptionally active regions was further supported by the 
association of PML bodies with many genes on the active X chromosome 
compared with their homologues on the inactive X chromosome, and with 
replication-dependent histone genes on chromosome 6 in S-phase cells compared 
with those in G0/G1 phase cells (Wang et al., 2004). 
PML bodies thus seem to associate with chromosomal regions of high 
transcriptional activity and/or gene density, and, in some cases, the association 
may be cell cycle-dependent. Yet, not all transcriptionally active regions of genome 
associate with PML bodies and PML bodies do not serve as obligate transcription 
sites for the associated genes that were tested, nor are basal transcription levels of 
these genes altered by knockdown of PML protein. Collectively, these observations 
suggest that the specificity of PML body association is determined by locus-specific 
factors rather then by the transcriptional level (Ching et al., 2005; Wang et al., 
2004). 
The genes brought into the vicinity of the PML body might then be jointly regulated 
through clustered co-activators such as CBP/p300, and co-repressors, such the 
histone deacetylases (HDACs). Such a role for PML bodies is reminiscent of that 
proposed for matrix attachment regions (MARs) in DNA (Cockerill and Garrard, 
1986). Furthermore, Kiesslich et al. (Kiesslich et al., 2002) found that, in 




associated with transcription foci, marked by the presence of hyper-phosphorylated 
RNA polymerase II and fluorouridine-labeled  newly synthesized RNAs; this 
percentage rose to 70% when cells were synchronized in G1. 
These findings may suggest, for  the PML bodies, a role analogous or coincident 
with the so-called “transcription factories”. These factories are discrete sites within 
the nucleus where RNA transcription occurs; growing evidence indicates that when 
a gene becomes active, its DNA moves to one of those factories. Genes on 
different chromosome whose proteins work together travel long distances within 
the nucleus to meet up in the same factories (Pennisi, 2006).  
On the other hand, several observations are also in sharp contrast with this 
conclusion. Knockdown experiments of PML bodies by RNA interference showed 
no effect on the expression of genes non-randomly associated with PML bodies 
(Wang et al., 2004). Experiments in the Ana Pombo laboratory have demonstrated 
by high-resolution imaging of ultrathin cryosections that PML bodies contain no 
detectable RNAPII or nascent RNA in HeLa cells, but are often surrounded by 
these markers at a distance >25 nm (Xie and Pombo, 2006). This observation 
supports the view that, although PML bodies are present in transcriptionally active 
areas of the nucleus, they are not themselves sites of polymerase assembly, 
transport or activity. One possible explanation for the difference between these 
results and those of Kiesslich et al. (Kiesslich et al., 2002) is that in vivo labeling of 
newly made RNA with fluorouridine allows for some transcripts to be completed 
and move away from the sites of synthesis towards PML bodies. Alternatively, the 
insufficient resolution provided by confocal microscopy of whole cells may give the 
false impression that PML bodies are transcriptionally active. Thus, the association 
of active genes with PML bodies, although nonrandom, can be explained by the 
coincidental positioning of PML bodies, active genes and polymerases in regions of 
the nucleus that are transcriptionally active (Wang et al., 2004). Proposed functions 
of PML bodies would agree with such preferential localization as they include 
storage of proteins, such as many transcription factors and chromatin modifiers, 
post-translational modification, like acetylation, phosphorylation and SUMOylation, 




These  results do not exclude the possibility that PML proteins that are freely 
available throughout the nucleoplasm (i.e. not in PML bodies) interact with RNAPII 
or regulate gene expression.  
Not only human genes, but also viral genomes associate with PML bodies. The 
genomes and/or replication complexes of HSV-1 and adenovirus were 
preferentially located in close association with PML bodies (Ishov and Maul, 1996; 
Maul et al., 1996). This observation has been extended to include the 
papovaviruses SV40 and polyomavirus, and members of all subfamilies of the 
herpesviridae (for reviews see (Everett, 2001; Maul, 1998)). More recently, similar 
observations were made in cells infected with the parvovirus AAV (Fraefel et al., 
2004).  
PML bodies not only are often  associated with viral genomes but also facilitate 
their transcription and replication (Ching et al., 2005), again supporting the 
hypothesis that these bodies are sites of gene activity. Regarding HIV-1, the group 
of G. Maul approached the localization of proviral HIV-1 DNA and transcribed HIV-
1 mRNAs with respect to speckles and PML bodies in the nucleus of infected cells 
(Bell et al., 2001). To distinguish between unintegrated and integrated viral DNA, 
these investigators employed a technique called stress-induced chromosome 
condensation (SICC), which allows the visualization of the interchromatin space. 
Surprisingly, unintegrated HIV-1 DNA was found to accumulate within nuclear 
speckles, while no specific association of either unintegrated viral DNA, or 
transcription foci, or integrated proviral DNA could be detected with PML nuclear 
bodies. However, given the fact that these experiments were conducted with a 
FISH probe covering the whole HIV genome, it should be considered that multiply 
spliced subgenomic mRNAs might have escaped detection by this method. These 
considerations still leave the question of what are the sites in the nucleus at which 
HIV transcription occurs with respect to the known nuclear territories, largely 
unanswered. 
Finally, it is of interest to note that, since PML bodies could also play a role in the 
mechanism of antiviral action of interferon, viruses have also evolved different 
ways to alter PML expression and/or localization (for review see (Everett, 2006; 




Function of PML bodies 
All the above reported observations on the properties of PML bodies may 
collectively lead to three possible models to explain their actual function.   
In the first model, the bodies are proposed to be aggregations of excess 
nucleoplasmic protein (Negorev and Maul, 2001): for example, they can sequester 
and inactivate co-activators, co-repressors or transcription factors (Li and Chen, 
2000; Zhong et al., 2000). By titrating these factors from the active pool in the 
nucleoplasm, the PODs could interfere with transcription, resulting in either 
activation or repression. 
In the second model, PML bodies are proposed to be sites of post-translational 
modification and degradation of proteins. Observations supporting this model 
include the acetylation (Pearson et al., 2000), phosphorylation (D'Orazi et al., 
2002) and sumoylation (Fogal et al., 2000; Kwek et al., 2001) of p53 at PML bodies 
and the localization of ubiquitin/proteasome associated proteins at some PML 
bodies (Anton et al., 1999; Everett et al., 1997; Lafarga et al., 2002; Lallemand-
Breitenbach et al., 2001). 
In the third model, PML bodies are proposed to be sites of specific nuclear 
activities, such as transcriptional regulation and DNA replication. Evidence for this 
model includes the detection of nascent RNA around PML bodies (Boisvert et al., 
2000), the association of PML bodies with regions of high transcriptional activity 
(Wang et al., 2004), and the non-random nature of PML body assembly (based on 
the conservation of their size and position) following dissociation and re-formation 
as a result of cellular stress (Eskiw et al., 2003).  





Post-translational modification represents an important mechanism for regulating 
protein function. Lysine acetylation, or the transfer of an acetyl group from acetyl 
coenzyme A to the ε-amino group of a lysine residue, was initially discovered on 
histone proteins about four decades ago (Vidali et al., 1968). Intensive research in 
the past decade has shown that this modification is quite common and plays 
important roles in regulating the functioning of eukaryotic, viral and bacterial 
proteins (Kouzarides, 2000; Sterner and Berger, 2000). Importantly, a protein 
module termed bromodomain has been shown to possess specific acetyllysine-
recognizing ability (Zeng and Zhou, 2002). 
 
Types of acetylated proteins Examples 
Core histones H2A, H2B, H3, H4 
Non-histone chromatin proteins HMGB 
HAT autoacetylation PCAF, p300 
Chromatin remodeler Brm 
Sequence specific transcription 
factors 
p53, STAT3, c-MYC, MyoD, E2F, Rb, NF-
kB 
Transcriptional co-regulators ACTR, CIITA, Rb 
General transcription factors TFIIE, TFIIF, PC4 
DNA replication factors MCM3, PCNA 
DNA metabolic enzyme 
Flap-endonuclease I, Werner DNA 
helicase 
Chromatin cohesion proteins Cohesin subunits, San 
Cytoskeletal proteins a-tubulin 
Apoptosis regulator Ku70 
Nucleocytoplasmic trafficking protein Importina 
Viral protein Adenoviral E1A, HIV Tat, HIV Integrase 
Bacterial protein Alba, CheY 
 





Lysine acetylation is a reversible post-translational modification that is governed by 
the opposing action of acetyltransferases and deacetylases (Grozinger and 
Schreiber, 2002; Yang, 2004). 
Since 1995 when the first acetyltransferase was discovered in yeast (Kleff et al., 
1995), dozen of proteins have been discovered to possess intrinsic lysine 
acetyltransferase activity. Although most of these enzymes were first identified as 
histone acetyltransferases (HAT) and then tested for activities towards other 
proteins, acetyltransferases only modifying non-histone proteins have also been 
identified. According to sequence similarity, lysine acetyltransferases can be 
organized into different groups.  
 
 
Figure 8. Schematic illustration of the Gcn5/PCAF (A) and p300/CBP (B) families 
of HATs (Yang, 2004). 
 
The Gcn5/PCAF family is composed of GCN5, PCAF and related proteins. Yeast 
Gcn5 possesses a HAT domain and a bromodomain and is highly homologous to 




(Georgakopoulos and Thireos, 1992; Smith et al., 1998; Wang et al., 1997; Xu et 
al., 1998). Numerous studies indicate that these HATs function as histone 
acetylating transcriptional co-activators but also that they can acetylate non-histone 
proteins as well (Yang, 2004). 
The p300/CBP family is another major group of nuclear HATs that has been 
extensively characterized (Chan and La Thangue, 2001; Goodman and Smolik, 
2000). Like PCAF, both p300 and CBP are transcriptional co-activators able to 
acetylate histones and non-histone proteins. Reminiscent of PCAF and GCN5L, 
p300 and CBP form a pair of homologous HATs in mammals.  
The MYST family of proteins constitutes a third major group of nuclear HATs. The 
acronym MYST is from its four founding members: human MOZ (monocytic 
leukemia zinc finger protein), yeast Ybf2, yeast Sas2 and the mammalian Tip60.  
Compared with the GCN5/PCAF and p300/CBP groups, the MYST family is larger, 
more diverse and not so well characterized. Despite their similar HAT domains, 
MYST proteins play different roles in various cellular processes (Yang, 2004).  
In addition to these three major groups of HATs, more than a dozen other proteins 
have been shown to possess acetyltransferase activity. 
Most HATs exist as stoichiometric multisubunit complexes in vivo. The complexes 
are typically more active than their respective catalytic subunits and display distinct 
substrate specificities, suggesting that associated subunits regulate the activities of 
the respective catalytic subunits. In addition, non-catalytic subunits are also 
involved in recruiting substrates for targeted action to ensure the specificity. 
Amazingly, one HAT can be the catalytic subunit of multiple complexes. GCN5L 
forms at least two distinct multisubunit complexes, and yeast GCN5 is the catalytic 
subunit of four complexes (reviewed in (Carrozza et al., 2003)).  
 
Regulation of HAT activity 
Multiple mechanisms are involved in the control of HAT activity (see (Yang, 2004) 
and references therein).  
First, as an essential cofactor for different acetyltransferases, acetyl-CoA also 




Second, as described above, formation of stoichiometric multisubunit complexes 
modulates the specific activities and substrate specificities of different HATs.  
Third, the enzymatic activities of PCAF, p300 and CBP are regulated by interaction 
with transcription factors and viral proteins. 
Fourth, HATs are subject to covalent modifications such as phosphorylation, 
acetylation, ubiquitination and sumoylation.  
Fifth, HATs are degradated by caspases, calpains and ubiquitin-dependent 
proteasomes.  
Sixth, subcellular compartmentalization is an important regulatory mechanism for 
HATs. For example, HAT1 binds to 14-3-3 proteins and TIP60 is sequestered to 
the cytoplasm in a signal-dependent manner.  
Finally, while p300, CBP, MOZ and MORF possess PHD fingers, yeast Esa1 and 
Sas3 associate with PHD finger-containing subunits. PHD fingers are implicated in 
phosphoinositide binding and may thus provide structural modules for integrating 
nuclear lipid signals, so that activities of these acetyltransferases may be regulated 
by nuclear signaling events. 
 
HDACs 
Two families of deacetylating enzymes have been identified in eukaryotes: the 
histone deacetylases,  or HDACs, and the Sir2 (silent information regulator-)-like 
family of NAD-dependent deacetylases, or sirtuins. Both families have been 
evolutionary conserved from prokaryotes  to humans, and both consist of several 
different proteins with non-redundant cellular functions, many of which involve 
transcriptional regulation. 
The HDAC family members can be divided into two classes based on their 
similarity to yeast histone deacetylase Rpd3 (class I) or Hda1 (class II) (Grozinger 
et al., 1999). Four class I (HDAC 1, 2, 3 and 8) and five class II (HDAC 4, 5, 6, 7, 9 
and 10) HDACs have been identified and partially characterized in humans (Gray 
and Ekstrom, 2001; Guardiola and Yao, 2002; Zhou et al., 2001). A third group of 
HDACs has been formed after the discovery of HDAC 11, which contains 




but seems to have distinct physiological roles from those of the known HDACs 
(Gao et al., 2002). 
HDAC1 and HDAC2 are the best characterized HDAC proteins and are generally 
found in stable, multicomponent complexes, which are recruited to their site of 
action by DNA binding proteins (Sin3, NuRD and CoREST complexes). 
The group of sirtuins is related to the yeast transcriptional repressor Sir2, and its 
members can be divided into five classes based on their primary structure (Frye, 
2000). Yeast Sir-2 is the best characterized sirtuin protein: it is found in two major 
complexes, one of which is responsible for silencing expression from the telomeric 
and HM loci, while the second one suppresses genetic recombination by forming a 
closed chromatin structure at the rDNA locus (Grozinger et al., 1999). 
Out of seven human sirtuins, only two have been characterized so far, but all seem 
to have weak or inexistent histone deacetylating activity in vivo. Sirt1 regulates 
processes such as apoptosis and muscle differentiation by deacetylating key 
proteins (p53, FOXO, PCAF, MyoD) (Hisahara et al., 2005; Vaziri et al., 2001; 
Yang et al., 2005). Sirt2 deacetylates alpha-tubulin (North et al., 2003) and is 
involved in the control of mitotic exit in the cell cycle, probably via its role in the 
regulation of cytoskeleton.  
 
Effects of acetylation on protein function 
The consequences of acetylation on protein function vary from one protein to 
another depending on the primary function of the protein and on where acetylation 
takes place.  
Acetylation has been reported to modulate DNA binding (Gu and Roeder, 1997; 
Marzio et al., 2000; Yao et al., 2001), protein-protein interactions (Bannister et al., 
2000; Cohen et al., 2004; Kovacs et al., 2005; Yuan et al., 2005), protein stability 
(Bernassola et al., 2004; Jeong et al., 2002; Li et al., 2002) and  subcellular 
localization (Blander et al., 2002; Kawaguchi et al., 2006; Kitamura et al., 2005; 
Thevenet et al., 2004).  
Both `loss-of-function' and `gain-of-function' effects have been reported. Regarding 
the former, acetylation of the ε-amino group of a lysine residue neutralizes the 




DNA, RNA and proteins. Such a mechanism may operate with chromatin since the 
DNA backbone is negatively charged. Indeed, histone acetylation has been shown 
to affect the nucleosomal structure and the stability of nucleosomal arrays (Garcia-
Ramirez et al., 1995). Alternatively, acetylation may render the ε-amino group 
unable to form hydrogen bonds. For example, Lys11 of Alba is involved in forming 
a hydrogen bond important for oligomerization, so acetylation of this residue 
inhibits oligomerization (Bell et al., 2002; Zhao et al., 2003). Acetyl-CoA synthetase 
from S. enterica provides another example of a `loss-of-function' effect (Starai et 
al., 2002). Lys609 of this enzyme is part of the catalytic center, so acetylation of 
this residue inhibits enzymatic activity. In eukaryotic cells, the ε-amino group of a 
lysine residue is also subject to methylation and modification by ubiquitin and 
ubiquitin-like proteins such as NEDD8 and SUMO. Different modifications are 
mutually exclusive, thus leading to their potential competition (Caron et al., 2005). 
As for `gain-of-function' mechanisms, the addition of an acetyl group to a lysine 
residue creates a new surface for protein association. Reminiscent of domains that 
recognize phosphoproteins, bromodomains function as structural modules specific 
for acetyllysine-containing motifs (Zeng and Zhou, 2002). It has been demonstrated 
that several chromatin regulators use bromodomains to recognize acetyllysine. 
Bromodomains are found in many proteins and sequence variations may dictate 
their binding specificity. Some proteins contain multiple bromodomains, which may 
cooperate with each other to increase the affinity for binding partners with multiple 
acetylated lysine residues. Acetylation is also known to stimulate the association 
with proteins that do not contain bromodomains (Soutoglou et al., 2000).  
Although the exact number and variety of proteins that are post-translationally 
lysine-acetylated in the cell is still unknown, it is clear that far more proteins are 
modified by this mechanism than initially appreciated. It has, thus been proposed 
that acetylation is a regulatory modification that rivals phosphorylation in spread 
(Kouzarides, 2000).  
Dynamic acetylation of non-histone proteins has pleiotropic effects on cellular 
function (see Table 2). Given this wide array of possible outcomes, it is not 





Effect of acetylation Examples 
Increases DNA binding affinity p53, SRY, STAT3, GATA1, GATA2, E2F1 
Decreases DNA binding affinity YY1, HMG-A1, HMG-N2, p65 
Increases transcriptional 
activation 





Increases protein stability P53, c-Myc, AR, E2F1, ERa, Smad7 
Decreases protein stability HIF1a 
Promotes protein-protein 
interaction 
STAT3, AR, EKLF, Importina 
Disrupt protein-protein interaction NF-kB, Ku70, Hsp90 
 
Table 2. Adapted from (Glozak et al., 2005) 
 
Acetylation and transcription 
The N-terminal tails of histones were the first acetyltransferase substrates to be 
discovered (Allfrey et al., 1964; DeLange et al., 1969; Vidali et al., 1968). Together 
with other modifications, such as methylation and ubiquitination, histone acetylation 
takes part in the determination of the histone code, a complex modification 
language that is fundamental to the regulation of chromatin structure and function 
(Strahl and Allis, 2000; Turner, 2000). Chromatin is typically repressive for nuclear 
processes like transcription (Horn and Peterson, 2002). Acetylation neutralizes the 
positive charge of the histone tails decreasing their affinity for DNA. As a 
consequence, histone acetylation loosens chromatin structure, an event that 
correlates with gene activation. Consistent with this notion, transcriptional co-
activators and co-repressors have been found to possess intrinsic HAT and HDAC 
activities, respectively (Carrozza et al., 2003; Grozinger and Schreiber, 2002). 
Except for a few cases (De Nadal et al., 2004; Wang et al., 2002), DNA-binding 
transcriptional activators recruit HATs to execute gene-specific chromatin 
acetylation and transcriptional upregulation, whereas repressors enlist HDACs to 




regulates other nuclear processes such as DNA replication, recombination and 
repair. Related to this, acetylation of histone H4 at Lys5 and Lys12 is required for 
deposition of newly synthesized core histones and chromatin assembly (Roth et al., 
2001). In addition to histones, other chromatin proteins like high-mobility group 
(HMG) proteins are also modified by acetylation (Bergel et al., 2000; Sterner et al., 
1979). 
As far as the other proteins involved in transcription are concerned, lysine 
acetylation is known to occur in over 40 sequence-specific transcription factors, in 
transcriptional co-regulators, general transcription factors and also chromatin 
remodellers (see Table 1). In several cases, this modification potentiates 
transcription. However, acetylation of NF-kB RelA, HMGI(Y), C/EBPb, IRF2, IRF7, 
Era, AFX, ACTR, TAFI68 and Brm inhibits transcription, which may serve as a 
feedback mechanism to control the duration of transcription.  
 
GCN5 
Gcn5 (general control of nonderepressible-5) has been the first link between 
histone acetylation and gene activation: as a matter of fact, the Tetrahymena 
histone acetyltransferase A was found to be homolog of S. cereviasie Gcn5, 
previously identified as a transcriptional co-activator (Brownell et al., 1996). 
Homologs of Gcn5 have been cloned and sequenced from numerous divergent 
organisms suggesting that their function is highly conserved throughout the 
eukaryotes (Brownell et al., 1996; Candau and Berger, 1996; Smith et al., 1998; Xu 
et al., 1998). 
To date, yeast Gcn5 is the best characterized of the HATs, both structurally and 
functionally and both in vivo and in vitro. Various studies have mapped and 
characterized the functional domains of this protein (Candau and Berger, 1996; 
Candau et al., 1997). These include a C-terminal bromodomain, an Ada2 
interaction domain, and the HAT domain, which was found to be required for 
transcriptional activation in vivo (Candau et al., 1997). Alanine scan mutagenesis 
identified conserved residues critical to HAT activity and demonstrated the direct 




promoter histone acetylation in vivo (Kuo et al., 1998; Wang et al., 1998). In 
addition to affecting the final steady state level of expression of a gene, Gcn5 can 
also significantly increase the rate of chromatin remodeling and gene activation, as 
it does for the PHO5  gene (Barbaric et al., 2001). 
The substrate specificity of Gcn5 has also been investigated. In vitro, recombinant 
Gcn5 was found to acetylate histone H3 strongly and H4 weakly in a free histone 
mixture. Protein sequence analysis of these reaction products revealed that the 
primary sites of acetylation were Lys 14 on histone H3 and Lys 8 and 16 on histone 
H4 (Kuo et al., 1996). Although recombinant Gcn5 can acetylate free histones 
efficiently, it is unable to acetylate nucleosomal histones, the more physiological 
substrate, except under special conditions and at high enzyme concentrations. 
Only in the context of multisubunit native complexes such as SAGA and ADA 
(described later) Gcn5 is able to acetylate nucleosomes effectively, indicating that 
the influence of other proteins is required to confer this activity.  
The human PCAF and GCN5 cDNAs were both identified based on their sequence 
similarity to yeast GCN5 (Candau and Berger, 1996; Yang et al., 1996). Two 
isoforms of the human GCN5 protein have been detected and are proposed to be 
the result of an alternative splicing event (Smith et al., 1998; Xu et al., 1998). The 
less abundant short form (GCN5S) is similar in length to yeast Gcn5p, whereas the 
predominantly expressed long form (GCN5L) contains an extended N-terminal 
domain akin to PCAF, mouse GCN5 and Drosophila GCN5 (Smith et al., 1998; Xu 
et al., 1998).  
The function of human GCN5 has also been investigated in vitro and in vivo, and it 
was found to carry out transcriptional adaptor roles analogous to those of yeast 
Gcn5. Further studies showed that human GCN5 had acetyltransferase activity and 
that its HAT domain could successfully substitute for that of yeast Gcn5 in vivo, 
indicating the evolutionary conservation of this HAT function (Wang et al., 1997). 
The HAT domain of human GCN5 is of course indispensable to its acetylation 
function, but interestingly, another domain appears to have an influence on its HAT 
activity and substrate use. While recombinant short-form human GCN5 could 
acetylate histone H3 (and to a lesser extent H4) only as free histones (Wang et al., 




competent for the acetylation of nucleosomal histones, implicating the N-terminal 
region in chromatin substrate recognition (Xu et al., 1998).  
GCN5 activity can be regulated by post-translational modifications. hGCN5 can be 
phosphorylated and inactivated by DNA-dependent protein kinase (Ku-DNA-PK) 
holoenzyme (Barlev et al., 1998); while yeast Gcn5 has recently been shown to be 
sumoylated (Sterner et al., 2006) 
 
Yeast GCN5-containing complexes 
As previously described, purified yeast Gcn5 is unable to acetylate nucleosomal 
histones under standard conditions in vitro. Because of this, a study was performed 
which sought to identify native yeast complexes capable of acetylating 
nucleosomal substrates. Two Gcn5-containing complexes were identified: SAGA 
and ADA (Grant et al., 1997). 
Of the known HAT complexes, yeast SAGA (Spt-Ada-Gcn5) is the best 
characterized (reviewed by (Sterner and Berger, 2000)). This 1.8 MDa complex is 
composed of more than 15 subunits and acetylates lysine residues on the histone 
H3 and H2B N-terminal tails. It comprises products of distinct classes of genes: the 
transcriptional adaptors (Ada proteins), the TATA-binding protein related set of Spt 
proteins; a subset of TBP-associated factors (TAFs) and Tra1, the yeast homolog 
of the human transcription regulatory protein TRAPP. 
Gcn5 is the catalytic HAT subunit of this complex (Grant et al., 1997) and is 
regulated by Ada2 and Ada3: Ada2 potentiates Gcn5 catalytic activity and interacts 
with acidic activators and Ada3 facilitates nucleosomal acetylation and an 
expanded lysine specificity (Balasubramanian et al., 2002; Grant et al., 1999; 
Sterner et al., 1999). It has been shown that SAGA also contains the de-
ubiquitylation enzyme Ubp8 which controls the levels of histone H2B ubiquitylation 
(Daniel et al., 2004; Henry et al., 2003) that are related to transcriptional activity 
(Bernstein et al., 2002; Daniel et al., 2004; Henry et al., 2003). 
The SAGA complex directly participates in the transcription process by being 
specifically recruited by activators to the promoter of many genes. For instance, 
activators such as Gal4 and Gcn4 interact directly with the SAGA complex in vitro 




et al., 1999; Sterner et al., 1999; Utley et al., 1998), and they recruit SAGA to target 
gene promoters in vivo (Kuo et al., 2000; Larschan and Winston, 2001), an event 
that can occur independently of transcription (Bhaumik and Green, 2001; Kuo et 
al., 2000; Topalidou and Thireos, 2003) and that precedes and is required for the 
recruitment of the RNAPII machinery to certain promoters (Bhaumik and Green, 
2001; Bryant and Ptashne, 2003).  
In some cases, SAGA recruitment seems to depend on the presence of other 
chromatin remodeling activities such as the SWI/SNF ATP-dependent nucleosome 
remodeling complex. The recruitment of one co-activator may stimulate the 
recruitment of another one, and this interdependence can be reflected in a 
sequential order of co-activators recruitment to the promoter. Such staged 
recruitment was shown for the HO gene where SWI/SNF recruitment is necessary 
for, and temporally precedes, recruitment of SAGA by the activator Swi5p to the 
URS2 element (Cosma et al., 1999). The requirement for SWI/SNF function as a 
prerequisite for SAGA recruitment by Swi5p at HO appears to be restricted to late 
mitosis and applies even to Gal4p- and Gcn4p-regulated promoters in this phase of 
the cell cycle, most likely reflecting a highly condensed state of promoter chromatin 
(Krebs et al., 2000). In fact, SAGA functions are required during interphase for wild-
type steady-state recruitment of SWI/SNF by Gcn4p at the target genes ARG1 and 
SNZ1 (Yoon et al., 2003). Thus, the degree of interdependency among co-
activators in recruitment can vary from one activator to the next, and even for the 
same activator depending on the chromatin structure of the promoter. 
Once recruited, the Gcn5 HAT subunit of SAGA locally acetylates histones, an 
event that facilitates transcription by loosening the chromatin structure or by 
generating specific binding sites for the recruitment of transcription factors (Kuo et 
al., 1998). 
SAGA can also serve an adaptor to recruit the TATA-binding protein (TBP) through 
its Spt3 subunit in a HAT-independent manner (Bhaumik and Green, 2001; 
Larschan and Winston, 2001). SAGA can thus substitute for TFIID at certain 
RNAPII genes. TFIID function seems to regulate the transcription of 90% of the 




10% of the genes, most of which seem to be stress induced (Huisinga and Pugh, 
2004).  
Although the exact mechanism remains to be determined, comparison of the low 
resolution structures of SAGA and yeast TFIID reveals important similarities and 
differences, which can be relevant for their function (Timmers and Tora, 2005; Wu 
et al., 2004). 
In addition to its targeted co-activator function, Gcn5 also acetylates histones 
genome-wide, a phenomenon affecting most nucleosomes in yeast  (Waterborg, 
2000) and referred to as "global acetylation" (reviewed in (Kurdistani and 
Grunstein, 2003)). This global activity results in a basal state of histone acetylation 
throughout the genome that varies among loci and over which targeted acetylation 
superimposes. While the importance of activator-targeted histone acetylation in 
transcriptional regulation has been extensively documented, the role of global 
acetylation remains largely elusive. A major complication in addressing this 
question stems from the ability of Gcn5 and other HATs to function in both a global 
and a targeted manner, thereby making it difficult to distinguish between the two 
activities.  
Global acetylation seems to affect the activation process by facilitating PIC 
formation, either by increasing the affinity of one or more general transcription 
factors for the core promoter or by creating a more accessible chromatin 
environment. The effects of this mechanism depend on the strength of interaction 
used to recruit the transcription machinery and on the affinity of the latter for the 
core promoter (Imoberdorf et al., 2006). 
The other known Gcn5-containing complex is ADA, which has a size of about 0.8 
MDa. Like SAGA, the ADA complex acetylates nucleosomes primarily on histone 
H3 and H2B in vitro but at fewer residues (Grant et al., 1999). It contains Ada2 and 
Ada3 but none of the other known subunits of SAGA (Grant et al., 1997). Peptide 
analysis revealed a novel subunit unique to ADA, demonstrating that it is a distinct 
complex and not a subcomplex or artifactual fragment of SAGA. This subunit, 
named Ach1 (ADA histone-acetyltransferase component 1), is specifically required 




(Eberharter et al., 1999). Although ADA does contain Gcn5 and two other 
adaptors, unlike SAGA it does not seem to participate directly in transcription.  
 
Human GCN5-containing complexes 
Human homologues of yeast Gcn5, PCAF and GCN5, were found in several 
multiprotein complexes, such as TBP-free TAF complex (TFTC) (Brand et al., 
1999; Wieczorek et al., 1998), SPT3/TAF9/GCN5 acetyltransferase complex 
(STAGA) (Martinez et al., 1998) and PCAF/GCN5 complexes (Ogryzko et al., 
1998). While still incompletely characterized, these multisubunit complexes show 
related, but not identical, compositions and presumably overlapping but also 
distinct functions. All contain Gcn5 or PCAF, Ada proteins, Spts, TAFs and TAF-
like proteins, in addition to the Tra1 orthologue, TRAPP 
(transformation/transcription domain-associated protein) (Martinez, 2002). 
However, TFTC specifically contained TAF5 and TAF6, whose yeast homologues 
are also found in SAGA, whereas these subunits were not found in STAGA or in 
PCAF/GCN5 complexes (Carrozza et al., 2003). Recently ataxin-7, the protein that 
harbors polyglutamine expansion in Spinocerebellar ataxia type 7, was shown to 
be a TFTC/STAGA subunit (Helmlinger et al., 2004). 
These complexes contain a GCN5 HAT activity and were shown to acetylate 
preferentially histone H3 in both free and nucleosomal contexts and to activate 
transcription on chromatin templates (Brand et al., 1999; Hardy et al., 2002; 
Martinez et al., 2001). Furthermore, TFTC has a TFIID-like function like yeast 
SAGA: it was shown to direct pre-initiation complex assembly in the absence TFIID 
on naked DNA templates (Wieczorek et al., 1998). In addiction  TFTC and STAGA 
complexes can associate with UV-damaged DNA-binding proteins suggesting a 
role for the complexes also in DNA repair mechanisms (Brand et al., 2001; 
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MATERIALS AND METHODS 
Plasmids and siRNAs 
pcDNA3-Cdk9-his was kindly provided by D.H. Price (Iowa City). From this 
template we subcloned Cdk9 in different expression vectors: pcDNA3 (Invitrogen) 
for in vitro translation, pGEX-2T (Amersham) for recombinant protein purification, 
pFlag-CMV-2 (Sigma) and pEGFP-C1 (Clontech) for expression in eukaryotic cells. 
pGEX-2T-Cdk9 deletion mutants were prepared by PCR amplifcation of Cdk9 with 
primers specific for the deleted versions. pGEX-2T and pFlag single and double 
mutants of Cdk9 were constructed using recombinant PCR starting from each 
original vector. 
Gal4-Cdk9 was generously provided by L. Lania (Napoli) (Majello et al., 1999). 
pG6(5’Pro) was obtained by  B.M.Peterlin (San Francisco).  
GST-CTD expressing bacteria were obtained from R. Young (Cambridge) 
(Hengartner et al., 1998). 
pGEX-GCN5  was a kind gift of M. Benkirane (Montpellier). 
pGEX-2T-GCN5 deletion mutants were obtained by PCR amplifcation of GCN5 
with primers specific for the deleted versions. 
pcDNA3-HA-GCN5  was prepared by subcloning of GCN5 in the pCDN3-HA 
vector. 
pcDNA3-HA-GCN5 (Y260A/F261A) (Paulson et al., 2002) was constructed using 
recombinant PCR starting from original vector.  
The pGEX-p300 HAT (aa 1195-1810) was a kind gift of  E. Verdin (San Francisco).  
pCMVβ-p300 has been previously described (Marzio et al., 1998; Marzio et al., 
2000). 
The pCMV p300DY-myc plasmid was kindly provided by T.P.Yao (Durham). 
The pcDNA3-PML-IV plasmid was obtained by S. Minucci (Milan) while the pFlag-
PML-IV by L. Banks (Trieste) (Guccione et al., 2004) 
 
siRNAs against GCN5 (Dharmacon-SMARTpool selected, 5’-
AACCAUGGAGCUGGUCAAUGA-3’) and  Luciferase (5’-
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NNAUGAACGUGAAUUGCUCAA-3’) (Palhan et al., 2005) were purchased from 
Dharmacon. 
 
Cell culture and transfection 
HEK 293T, U2OS and HeLa cells were maintained in Dulbecco modified Eagle’s 
medium (DMEM) supplemented with 10% fetal bovine serum, penicillin (100 U/ml) 
and streptomycin (1 mg/ml). Transfection were performed by the standard calcium 
phosphate co-precipitation procedure or by Polyfect or Effectene (Qiagen) 
according to the manufacturer’s instructions. 
Deacetylation inhibition was achieved by treatment of cells with trichostatin A (TSA) 
200 ng/ml over night. 
 
Recombinant proteins 
Recombinant GST fusion proteins were produced and purified from BL21 bacteria 
transformed with the respective plasmids. Bacterial culture were growth in terrific 
broth + ampicillin and protein production was induced with IPTG 0.5 mM for 4 
hours at 30 °C with OD600 between 0.6 and 0.8. Bacteria where then resuspended 
in lysis buffer (50 mM Tris-HCl pH 8, 100 mM NaCl, 5% glycerol, 2 mM 
dithiothreitol) and sonicated by 4 pulses of 30 sec each. Bacterial lysates were 
mixed with a 50% (vol/vol) slurry of glutathione cross-linked agarose beads and the 
GST-fusion proteins were allowed to bind the beads at 4 °C on a rotating wheel for 
1 hour. The suspension was then loaded on an empty plastic column (Bio-Rad, 
Richmond, CA), letting the unbound proteins pass through, and the beads were 
washed in 400 beds volumes of lysis buffer. The fusions proteins were eluted in the 
elution buffer  (100 mM Tris-HCl pH 8, 100 mM NaCl, 5% glycerol, 2 mM 
dithiothreitol) containing 20 mM free glutathione. The purity and integrity of the 
proteins were routinely checked by SDS-PAGE and Coomassie blue staining. 
 
In vitro acetylation assay  
HAT assays were performed as previously reported with minor modifications 
(Marzio et al., 1998; Marzio et al., 2000). GST fusion proteins used as substrates 
were incubated with the GST-GCN5 or GST-p300 HAT and [14C]-acetyl-CoA in 
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HAT buffer (50 mM Tris pH 7.5, 5% glycerol, 0.1 M EDTA, 50 mM KCl, and 2 mM 
sodium butyrate) in a final volume of 20 µl for 45 min at 30°C. Acetylated proteins 
were visualized by phosphoimaging (Cyclone) after separation by SDS-PAGE.  
 
In vitro binding assays 
[35S]-labelled Cdk9 proteins used for in vitro binding assays were produced by 
using the TNT Reticulocyte Lysate System (Promega) and the corresponding 
pcDNA3 vectors as templates. 
Binding of GST-GCN5 and its truncated variants to [35S]-Cdk9 was performed as 
previously described (Marzio et al., 1998; Marzio et al., 2000). Briefly, 1 µg of 
recombinant proteins immobilized on agarose beds, after pretreatment in a solution 
containing DNaseI 0.25U/µl and RNase 0.2 µg/µl to remove contaminant bacterial 
nucleic acids, were washed and resuspended in NETN buffer ( 20 mM Tris-HCl pH 
7.5, 100 mM NaCl, 1mM EDTA, 0.5% NP-40, 1mM DTT, 1mM PMSF) 
supplemented with 0.2 mg/ml of ethidium bromide to inhibit aspecific interactions 
between residual DNA and proteins. In vitro translated [35S]-labeled proteins were 
added and incubated  at 4 °C on a rotating wheel. After 1 hour, bound proteins 
were washed 5 times with 1 ml of NETN buffer and then resolved by SDS-PAGE 




For the production of a polyclonal, anti-acetylated Cdk9 antibody three rabbits were 
immunized with a 15-mer Cdk9 peptide (residues 39-53) acetylated at positions 44 
and 48 after conjugation with keyhole limpet hemocyanin (Sigma). The IgG fraction 
was obtained from serum with ImmunoPure (A) IgG purification kit (Pierce). The 
antibody was tested by dot blot and western blot analysis. 
The following antibodies were used: anti-acetylated lysine (Cell Signaling); anti 
Flag (M2 Sigma), either free or bound to agarose beads; anti HA (Y-11), anti Cyclin 
T1 (T-18) anti Cdk9 (C-20 and D-7), anti GCN5 (H-75), anti p300 (N-15), anti PML 
(PG-M3) all purchased from Santa Cruz; anti HEXIM1 kindly provided by O. 
Bensaude (ENS, Paris); anti Ac-Cdk9 (see above). 
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Immunoprecipitation and in vivo acetylation assay  
For immunoprecipitation cell pellets were lysed 36 hours after transfection in a 
NHEN buffer (20 mM Hepes pH 7.5, 300 mM NaCl, 0.5% NP-40 20% glycerol, 1 
mM EDTA) or RIPA buffer  (50mM Tris-HCl pH 7.5, 150 mM NaCl, 1% TRITON X-
100, 0.1% SDS, 0.5% deoxycolic acid) containing 10 mM of sodium butyrate 
(Sigma) and protease inhibitors (Roche). The protein concentration of the extracts 
was determined by the Bradford assay (BioRad). Specific antibodies were 
incubated overnight at 4°C with cell extracts (2 mg). Next, 30 ml of a 50% 
suspension of protein-A-trisacryl beads (Pierce) was added. After 2 hours of 
incubation  the immuno-complexes were extensively washed in lysis buffer and 
then analyzed by western blotting.  
 
Immunoprecipitation-kinase assay and FSBA labeling 
For kinase assays phosphatase inhibitors were added to the NHEN lysis buffer (20 
mM NaF, 1mM Na3VO4). Anti-FLAG M2 agarose beads were incubated overnight 
at 4°C with 500 μg of cell extract and then extensively washed with NHEN + 20 mM 
NaF.  IP beads were then washed twice with kinase buffer (50 mM Tris-HCl pH 7.4, 
5 mM MgCl2, 5 mM MnCl2, 20 mM NaF) and finally incubated in 20 μl of reaction 
buffer (kinase buffer + 10 μM ATP + 2.5 mM DTT) with 5 μCi  of [32P] ATP  and 
GST-CTD beads (containing 1 μg of proteins) for 30 min at 30 °C. Reaction was 
stopped by adding SDS sample buffer and boiling. Phosphorylated proteins were 
visualized by phosphoimaging (Cyclone) after separation by SDS-PAGE. 
For FSBA labeling Flag immunoprecipitation was conducted in the same way. After 
extensive washing with NHEN buffer, Flag-beads were incubated with FSBA 50 mM 
(alone or in presence of ATP 0.5 or 5 mM)  in PBS+0.1% TritonX-100 for 15 min at 
30 °C, then washed 4 times with PBS+0.5% TX-100. Proteins were resolved by 
SDS-PAGE and then subject to western blot with an anti-FSBA antibody kindly 
provided by M. Wymann (Basel) (Wymann et al., 1996).  
All quantifications experiments were performed at least three times. 
 




U2OS cells were seeded in 6-well plates and transfected with Polyfect (Qiagen) 
with the indicated plasmids and  siRNAs. In each transfection 200 ng of pEGFP-C1 
(Clontech) were co-transfected as an internal control. After 48 hours cells were 
harvested and part of them analyzed by flow cytometry for transfection efficiency. 
The remaining part  was resuspended in 200 μl of Tris-HCl 0.25M pH 8 and lysed 
by repeated freeze/thaw cycles. The protein concentration of the extracts was 
determined by the Bradford assay (BioRad) and then 2.5 μg of lysate were used to 
measure CAT expression with a CAT ELISA kit (Roche) according to the 
manufacturer's instructions. 
The results were reported as percentage of CAT production with respect to the 
values obtained by transfecting  only the reporter pG6(5’Pro) and the activator 
Gal4-Cdk9.  
Each experiment was repeated at least three times. 
 
Immunofuorescence 
Following paraformaldehyde fixation, cells were washed with 100 mM glycine and 
permeabilized with 0.1% Triton X-100 for 5 min. Primary and secondary antibodies 
were incubated at 37°C for 1 h in a humidified chamber in phosphate-buffered 
saline with the addition of 1% bovine serum albumin and 0.1% Tween-20. Images 
were acquired using a TCS-SL Leica confocal microscopy. 
 
Biochemical fractionation 
Biochemical fractionation assays were conducted as described by Fogal et al. 
(Fogal et al., 2000). Briefly 36 hours post transfection cells were collected in PBS 
and nuclei were separated by lysis in buffer 1 (50 mM Tris-HCl pH 7.9, 10 mM KCl, 
1 mM EDTA, 0.2% NP-40, 10% glycerol) and centrifugation at 6000 r.p.m. for 3 min 
at 4 °C. Pellets were washed in buffer 1 without detergent and lysed in buffer 2 
(400 mM NaCl, 1% NP-40, 20% glycerol, 20 mM HEPES pH 7.9, 10 mM KCl, 1mM 
EDTA) for 20 min at 4 °C. The insoluble and soluble nuclear fractions were 
separated by centrifugation at 14000 r.p.m. for 10 min. 
 




After treatment with TPA for the indicated time periods, cells were fixed by adding a 
fixing solution (11% formaldehyde, 100 mM NaCl, 1 mM EDTA, 0.5 mM EGTA pH 
8.0, 50 mM Tris–HCl pH 8.0) directly to the cell culture medium at 1% final dilution. 
Cross-linking was allowed to proceed for 10 min at 37°C and was stopped by the 
addition of glycine at a final concentration of 0.125 M. Fixed cells were washed 
once in ice-cold PBS, once in buffer B1 (0.25% Triton X-100, 10 mM EDTA, 0.5 
mM EGTA, 10 mM Tris–HCl pH 8.0) and once in buffer B2 (1 mM EDTA, 0.5 mM 
EGTA, 200 mM NaCl, 10 mM Tris–HCl pH 8.0). Cells were pelletted by 
centrifugation and resuspended in RIPA 50 buffer (50 mM NaCl, 20 mM Tris–HCl 
pH 7.4, 1 mM EDTA, 0.5% NP-40, 0.5% deoxycholic acid, 0.1% SDS, protease 
inhibitors). Chromatin was sheared by sonication (20 pulses, 30 s each) on ice and 
centrifuged to pellet debris. Immunoprecipitations were carried out using the 
antibodies indicated (4 µl of each antibody) [Pol II (H224) SC-9001; CDK9(H-169) 
SC-8338 (all from Santa Cruz); Pol II phosphorylated at Ser 2 in CTD (H5) from 
Covance; Ac-CDK9 previously described] at 4°C overnight. Immune complexes 
were collected with protein A–Sepharose CL-4B (Pharmacia), and beads were 
washed three times with 1 ml RIPA 150 buffer (same as RIPA 50 but with 150 mM 
NaCl). Protein–DNA complexes were resuspended in 200 µl of TE buffer and 
digested with 5 U of DNase-free RNase (Roche) for 30 min at 37°C. The samples 
were treated for 3 h at 56°C with 300 µg/ml Proteinase K (Sigma) in 0.5% SDS, 
100 mM NaCl, and for 6 h at 65°C to revert crosslinks. DNA was extracted with 
phenol/chloroform/isoamyl alcohol, ethanol precipitated and resuspended in water 
for PCR quantification. 
Diluted concentrations of the input (1/10 and 1/100) were used as standards for 
each primer and TaqMan probe set. Real Time PCR amplifications were performed 
on an  AbiPrism 7000 machine, using the TaqMan technology (Applied 
Biosystems) with ChIP products standardized for primer efficiency. Fold 
enrichments (occupancy) for each of the antibodies were calculated as a percent of 
the input material.  
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Details of primers used in ChIP analysis: 
Primer Name Sequence Position 
PPR1  For GCCTCCTAGCATTTCGTCAC  271 
PPR1  Rev CTCGATGTCAGCAGTTCTTTGTAGT  298 
PPR1  Probe AGAGCTGCATCCGGA 316 
NUC1A  For GCTAGCTAGGGAACCCACTGCTTA  497 
NUC1A  Rev CTACAAGTAGTGTGTGCCCGTCT  556 
NUC1A  Probe CCTCAATAAAGCTTGCC  532 
U1A  For ACATCAAGCAGCCATGCAAAA 1368 
U1A  Rev CAGAATGGGATAGATTGCATCCA  1418 
U1A  Probe AAGAGACCATCAATGAGGAA 1394 
U1B  For TCAGAAGCAGGACCCGATAGA  2208 
U1B  Rev TCACTCTTTGGCAGCGACC 2250 
U1B  Probe ACTGTATCCTTTAGCTTCCCT 2225 
U1C  For ATGAAGGGTGCCCACACTAATG 3618 
U1C  Rev CAAAAAATAGCCACAGAAAGCATAGTAA 3667 

















Cdk9 interacts with and is acetylated by GCN5 
Cdk9 is acetylated by GCN5 acetyltransferase 
It has been shown that Cdk9 is regulated by post-translational modifications such 
as phosphorylation (Fong and Zhou, 2000; Garber et al., 2000; Zhou et al., 2001) 
and ubiquitination  (Barboric et al., 2005; Garriga et al., 2003; Kiernan et al., 2001). 
Because a growing number of nonhistone regulatory proteins are covalently 
modified by acetylation (reviewed in (Glozak et al., 2005)) we decided to 
investigate  whether Cdk9 is also acetylated.  
First we wondered whether Cdk9 was acetylated in vivo. To this end we 
immunoprecipitated Flag-Cdk9 or Flag-Luciferase (as a negative control) from 
293T transfected cells and probed the immunoprecipitated protein with an antibody 
that specifically recognizes acetylated lysines (Figure 9A left panel). This 
experiment revealed that Flag-Cdk9, but not Flag-Luciferase, was acetylated in 
vivo by endogenous acetyltransferases even if the two proteins were equally 
expressed. To confirm this result we proved that treatment of cells with trichostatin 
A (TSA), a potent inhibitor of different HDAC activities (Yoshida et al., 1995), 
increased the Flag-Cdk9 acetylation signal (Figure 9B).  
In an attempt to identify which histone acetyltransferase (HAT) is responsible for 
Cdk9 acetylation, we tested the activity of the GCN5 and p300 enzymes, chosen 
as prototypes of the two best characterized families of HATs which are involved in 
transcriptional co-activation (Yang, 2004). We repeated the in vivo acetylation 
assay by transfecting 293T cells with Flag-Cdk9 and either p300 or HA-GCN5 wild 
type or catalytically inactive mutants. Expression of wild type GCN5, but not of the 
inactive mutant (Y260A/F261A) was found to remarkably increase Cdk9 
acetylation, while p300 had only a modest effect, which was lost completely by 
using its catalytically inactive variant (Figure 9C). Western blot analysis with the 
anti-Flag antibody revealed that the same amount of proteins were expressed and 
immunoprecipitated even in case of HATs co-transfection. Note that the basal level 




since their exposure time was significantly shorter, in order to visualize the high 
level of Cdk9 acetylation that follows GCN5 transfection.  
 
 
Figure 9. Cdk9 is acetylated by GCN5 in vivo and in vitro. (A and B) In vivo 
CDK9 acetylation. Extracts from HEK 293T cells transfected or treated as indicated 
on top of each lane were immunoprecipitated with an anti-Flag antibody and then 
immunoblotted with an anti-Ac-Lys antibody. The same filters were then incubated 
with an anti-Flag antibody. (C) Same as in (A) and (B) for the upper three panels. 
The bottom three panels show transfected protein levels. WCL: whole cell lysate 
(D) In vitro CDK9 acetylation. Recombinant purified GST-CDK9 was incubated with 
GST-GCN5 or GST-p300 HAT in the presence of radioactive labeled [14C]-acetyl-
CoA and resolved by SDS-PAGE followed by autoradiography (upper panel). 
Lower panel shows Coomassie blue staining of the same gel. 
 
These findings suggested that GCN5 was the major responsible for the observed 
acetylation of Cdk9. To further confirm this finding, we performed an in vitro 
acetylation assay. Recombinant full length GST-Cdk9 was incubated with 




radioactive labeled acetyl-CoA and resolved by SDS-PAGE followed by 
autoradiography (Figure 9D).  While the GST protein, used as a negative control, 
gave no autoradiographic signal, GST-Cdk9 gave an acetylation signal with both 
acetyltransferases, but stronger with GCN5. In addition to Cdk9, p300 and GCN5 
were also positive for acetylation due to the autocatalytic activity of the enzymes 
(Creaven et al., 1999; Thompson et al., 2004), thus demonstrating that both HAT 
proteins were enzymatically active.  
This experiment confirmed that GCN5 is a specific acetyltransferase for Cdk9 both 
in vivo and in vitro. 
 
Cdk9 interacts with GCN5  
Unlike classical enzyme substrates, most known acetylated proteins associate with 
their respective acetyltransferases, thus we decided to explore whether GCN5 
binds Cdk9 and which are the regions that mediate this interaction. 
For this experiment we performed immunoprecipitation of GCN5 from HeLa total 
and nuclear extracts and analyzed bound proteins by Western blot using a specific 
anti-Cdk9 antibody. Cdk9 could be detected together with GCN5 in the bound 
fraction (Figure 10A).  
To confirm this interaction, a Flag tagged Cdk9 was expressed in 293T cells 
together with HA-GCN5 wild type or mutated in the catalytic domain 
(Y260A/F261A), followed by immunoprecipitation using an anti-Flag antibody and 
immunoblotting with an anti-HA antibody. As shown in the upper panel of Figure 
10B, HA-GCN5 wild type and mutated specifically co-precipitated with Flag-Cdk9, 
while they did not with the pFlag empty vector. In a consistent manner, Flag-Cdk9  
was found to co-immunoprecipitate with HA-GCN5  when the immunoprecipitation 
was performed with HA antibodies. It is interesting to note that both GCN5 wild 
type and the catalytically inactive mutant (Y260A/F261A) were able to co-
immunoprecipitate with Cdk9 suggesting that the interaction between the two 
proteins did not depend on the HAT activity of GCN5. The same extracts were run 
on an SDS-PAGE gel and immunoblotted with anti-Flag and anti-HA antibodies to 





Figure 10. Cdk9 binds GCN5 in vivo. (A) HeLa whole cell lysate  and nuclear 
extract (NE) were subject to immunoprecipitation with an anti-GCN5 antibody and 
then analyzed by western blotting using a specific anti-CDK9 antibody. CDK9 could 
be detected together with GCN5 in the bound fraction. (B) Extracts prepared from 
cells co-transfected with Flag-CDK9 and wt HA-GCN5 or HA-GCN5(Y260A/F261A) 
were immunoprecipitated with an anti-Flag antibody and immunoblotted with anti-
HA antibody and vice versa (upper four panels).  The same extracts were run on 
an SDS-PAGE gel and immunoblotted with anti-Flag and anti-HA antibodies to 
verify protein expression levels (lower two panels). 
 
Having established that GCN5 and Cdk9 interact in vivo, we set out to dissect the 
regions that mediate this interaction. 
To map the Cdk9 interacting domain in GCN5, the latter was divided into four 
fragments which were subsequently cloned and expressed as GST fusion proteins. 
Therefore we produced a GST-GCN5 full length (aa 1-476), and four deletions 
mutant that we called N-terminal domain (aa 1-189), HAT domain (aa 190-270), 
Intermediate domain (aa 270-383) and Bromo domain (aa 384-476); Figure 11A.  
GST pull-down experiments with these fragments were performed using in vitro 
translated [35S]-labeled Cdk9. GST-GCN5 fragments immobilized on beads were 
incubated with [35S]-Cdk9; the beads were then extensively washed and the 





Figure 11. The N-terminus of Cdk9 binds GCN5 Bromo and HAT domains  in 
vitro. (A) CDK9 binds the bromo- and HAT-domains of GCN5 in vitro. Schematic 
representation of the GST-GCN5 fragments used for pull down assays. (B) GST-
GCN5 fragments were incubated with [35S]-CDK9, extensively washed and then 
analyzed by SDS-PAGE. (C) GCN5 binds the N-terminus of CDK9 in vitro. 
Schematic representation of the [35S]-CDK9  deletion mutants used for pull down 
assays. The position of the lysines that are positive for acetylation is indicated by 
an asterisk. (D) GST-GCN5 or GST alone as a control were incubated with [35S]-
CDK9 deletion mutant proteins, extensively washed and then analyzed by SDS-
PAGE. The upper panels in (B) and (D)  show the gels exposed to a 
phosphoimager screen, while the lower panels the Coomassie stainings of the 
same gels. The bands corresponding to the relevant intact GST proteins are 
indicated by asterisks. The graphs show the amounts of bound proteins as 
percentages of radiolabeled input. 
 
Figure 11B shows the gel stained with Coomassie blue (upper panel) and after 
autoradiography (lower panel). Labeled Cdk9 was found to bind to GST-GCN5 full 
length,  but not to GST alone. Among the four GCN5 fragments, Cdk9 bound 




comparable to background signal. Thus the region of GCN5 responsible for the 
interaction with Cdk9 includes the Bromo and HAT domains. This is not surprising 
since the bromodomain has a specific affinity for acetyllysine containing motifs 
(Dhalluin et al., 1999; Hudson et al., 2000; Owen et al., 2000) and the HAT domain 
is the catalytic domain that has to contact the substrate in order to transfer the 
acetyl group. 
To map the GCN5 interacting domain on Cdk9, a series of [35S]-labeled Cdk9 N-
terminal deletion mutants were produced and tested for GST-GCN5 binding. Based 
on the homology between Cdk9 and the best characterized kinase, Cdk2 (Grana et 
al., 1994), we produced four Cdk9 mutants. Cdk9 (41-372) lacks subdomain I 
containing the glycine-rich loop of the ATP-binding site; Cdk9 (50-372) includes 
half of the subdomain II but lacks the lysine 48 that is homolog to the conserved 
Cdk2 K33 needed for maximum enzyme function (De Bondt et al., 1993); Cdk9 
(74-372)  includes domains IV-XI and lacks the PITALRE region that is responsible 
for the interaction with the cyclin partner; Cdk9 (161-372) contains domains VII-XI 
that include the T-loop which is the activation region of the molecule (Figure 11C). 
As shown in Figure 11D, only wild type Cdk9 and Cdk9 (41-372) were able to bind 
GCN5 above background level. These results suggest that Cdk9 can specifically 
interact with GCN5 through the region comprised between its amino acids 41 and 
50.  
Given these data, we concluded that the N-terminus of Cdk9 interacts with the 
Bromo and HAT domains of GCN5. 
 
Acetylation modifies crucial residues of Cdk9 
Cdk9 is acetylated at lysine 44 and 48 by GCN5 
In order to determine which portion of Cdk9 was acetylated by GCN5 we produced 
N- and C-terminal Cdk9 deletion mutants fused to GST, as schematized in Figure 
12A, and then analyzed them by the in vitro HAT assay.  
As shown in Figure 12B lanes 3 and 4, the deletion of the first 41 aa of the protein 




to include the first 74 aa (thus also removing the PITALRE region), acetylation of 
the protein became undetectable.  
Between amino acid 41 and 74 there are two groups of lysines: the first one 
between aa 41-50 (K44, 48 and 49) and the second one in between aa 50-74 (K56 
and 68). Therefore we tested a new GST-Cdk9 deletion mutant  spanning amino 
acids 50-372 that only contained the second group of lysines and that was found to 
be negative for acetylation (Figure 12B lane 11). Thus the region that is target for 
GCN5 acetylation lies between amino acids 40 and 50. Noteworthy, this is the 
same region that was found to interact with GCN5. 
Since this region contains three lysines at positions 44, 48 and 49, they were 
changed, either one at a time or in combination, into arginines (this amino acid is 
characterized by the same positive charge as lysine, but cannot be modified by 
acetylation). 
None of the single mutants was negative for acetylation (Figure 12B lanes 
12,13,14), while the double mutant K44,48R was negative (lane 15). From this set 
of experiments, we concluded that the lysines at positions 44 and 48 are substrates 
for GCN5-mediated acetylation. 
To confirm that Cdk9 is acetylated by GCN5 at positions 44 and 48 also in vivo we 
cloned Cdk9 K44,48R in a Flag-tagged expression vector. Using this mutant and a 
wild type Cdk9 expression vector, we performed an in vivo acetylation assay. Upon 
GCN5 overexpression, Flag-Cdk9 was found to be markedly acetylated, while the 
mutant Flag-Cdk9 K44,48R was negative for acetylation even if the two Flag 
proteins were expressed and immunoprecipitated to the same extent (Figure 12C). 
To exclude the possibility that the substitution of Lys 44 and Lys 48 (that lie in the 
region of Cdk9 that interacts with GCN5) might disrupt the interaction between 
Cdk9 and GCN5, we also immunoblotted the same filter with a GCN5 antibody and 
found that both Flag-Cdk9 and Flag-Cdk9 K44,48R were able to co-
immunoprecipitate GCN5 at the same efficacy  (Figure 12C, bottom panel). This 
result implies that loss of acetylation in the K44,48R mutant does not result from its 
inability to associate with GCN5, but from the fact that K44 and 48 are authentic 





Figure 12. Mapping of Cdk9 acetylation site in vitro and in vivo. (A) Schematic 
representation of GST-CDK9 fragments used for in vitro acetylation assays. 
Position of lysines found to be positive for acetylation is indicated by an asterisk. 
(B) In vitro mapping of CDK9 acetylated lysines. Full length CDK9 (lane 2); a series 
of CDK9 mutants with N- and C-terminal truncations (lanes 3-7 and 10-11); and 
point mutants in the lysines in the N-terminal domain (lanes 12-16) were assayed 
for in vitro acetylation by GCN5. Proteins were resolved by SDS-PAGE followed by 
autoradiography. (C) In vivo mapping of CDK9 acetylated lysines. Extracts of 293T 
cells transfected with the indicated plasmids were immunoprecipitated with an anti-




same filter was incubated with an anti-Flag antibody (medium panel) and an anti-
GCN5 antibody (lowest panel) to verify protein expression levels. Of notice the 
CDK9 (K44,48R) mutant, which is not acetylated, is still able to bind GCN5. 
 
Cdk9 K44,48R has impaired catalytic activity 
Interestingly, the acetylated lysines of Cdk9 lay in close proximity to the PITALRE 
amino acid sequence (position 60-66). This region is essentially involved in the 
formation of the catalytic pocket of Cdk9, and its sequence is highly conserved in 
all members of the Cdk family (Figure 13A). In particular, lysine 48 of Cdk9 
corresponds to lysine 33 of Cdk2; structural data indicate that this residue is 
essentially involved in orienting the ATP phosphate residues as well as in 
magnesium binding within the catalytic pocket of the enzyme (De Bondt et al., 
1993). 
This prompted us to investigate whether mutations in this lysine could modify the 
enzymatic properties of Cdk9 . 
First, we transfected U2OS cells with the Flag-Cdk9 K44,48R expression vector 
and analyzed the subcellular localization of the mutated protein by 
immunofluorescence with an anti-Flag antibody: Cdk9 K44,48R had a nucleo-
cytoplasmic localization analogous to that of wild type Cdk9 (Figure 13B). 
Then in order to assess the binding between Flag-Cdk9 K44,48R  and the 
regulatory partners CyclinT1 and HEXIM1, we transfected 293T cells with Flag-
Cdk9 wild type or K44,48R and performed immunoprecipitations of the two proteins 
with an anti-Flag antibody. Western blot analysis revealed that endogenous 
CyclinT1 co-precipitated with the same efficacy with both proteins, while HEXIM1 
showed slightly decreased affinity for the mutated form of Cdk9 (Figure 13C). 
Nevertheless the major expected effect of lysines mutation was an impairment of 
Cdk9 catalytic activity. Therefore we set out to measure Cdk9 kinase activity by 
immunoprecipitation-kinase assay. Flag-Cdk9 wild type or K44,48R mutant were 
immunoprecipitated from 293T transfected cells with an anti-Flag antibody and 
then after extensive washing incubated with recombinant GST-CTD purified from 
bacteria and [32P]-radiolabeled ATP. The complexes were then resolved by SDS-





Figure 13. Cdk9 K44,48R characterization. (A) Conservation of one of the 
lysines that are substrates for acetylation (K48) in other Cdks controlling 
transcription or cell cycle. (B) U2OS cells were transfected with Flag-Cdk9 
K44,48R and then subject to immunofluorescence with an anti-Flag antibody. (C) 
293T cells were transfected with Flag-CDK9, either wild type or K44,48R and then 
subject to immunoprecipitation with an anti-Flag antibody. CyclinT1 and HEXIM1 




panels show protein expression levels in whole cell lysates. (D) Mutations of 
lysines 44 and 48 to arginines inhibits CDK9 kinase activity. Flag-CDK9, either wild 
type or K44,48R, immunoprecipitated from 293T cells, and recombinant GST-CTD, 
purified from bacteria, were incubated with [32P]-radiolabeled ATP and then 
resolved by SDS-PAGE followed by autoradiography. The graph shows the 
quantification of labeled GST-CTD in three independent experiments (mean±s.d.). 
The bottom panel shows protein expression levels. (E) CDK9 K44,48R mutant has 
reduced ATP binding activity. Wild type Flag-CDK9 or its K44,48R mutant were 
transfected into 293T cells, immunoprecipitated with an anti-Flag antibody and 
labeled with the ATP analog FSBA. Immunoprecipitated proteins were then 
resolved by SDS-PAGE and analyzed by western blot  with an anti-FSBA antibody 
(upper panel) or anti Flag antibody (lower panel). Incorporation of FSBA was then 
quantified by densitometric analysis. The graph shows the mean±s.d. of three 
independent experiments. 
 
The Cdk9 K44,48R mutant had a significantly reduced kinase activity in 
comparison to wild type Cdk9 even if it was  expressed to the same level (Figure 
13D).  
To examine whether the loss of kinase activity was due to the failure to bind ATP, 
we utilized the ATP analog FSBA to measure the ATP binding capacity of the two 
proteins. In fact FSBA contains a crosslinking group in the position analogous to 
the g-phosphate of ATP (Kamps et al., 1984) whose transfer and correct 
positioning are probably regulated by the conserved lysine positioned in the 
catalytic pocket of protein kinases.  
Immunoprecipitated wt or K44,48R mutant Flag-Cdk9 were extensively washed 
and then  incubated with 50 mM FSBA in the presence or absence of competitor 
ATP for 15 min at 30 °C. Then the proteins were resolved by SDS-PAGE and 
FSBA incorporation was revealed by western blot with an anti-FSBA antibody 
(Wymann et al., 1996), while the amount of immunoprecipitated proteins was 
assessed with anti-Flag antibody (Figure 13E).  In keeping with previous results, 
quantification of the ratio between (FSBA labeled protein) and (total 
immunoprecipitated Flag protein) by densitometric analysis revealed that Flag-
Cdk9 K44,48R mutant had reduced capacity to bind FSBA in comparison to wild 
type Flag-Cdk9. We proved that the FSBA labeling was specific for the nucleotide 




FSBA for the binding to the kinase and at higher doses completely abolished the 
FSBA labeling. 
 
Acetylation inhibits Cdk9 kinase and transcriptional activity 
GCN5 mediated acetylation inhibits Cdk9 kinase activity. 
Since we found that the lysines that are acetylated by GCN5 are crucial for Cdk9 
kinase activity, we wondered what effect could have the addition of an acetyl group 
on these residues in the context of the wild type Cdk9 protein. As a matter of fact 
acetylation of residues in the catalytic site of other enzymes has been shown to 
inhibit their function (Hallows et al., 2006; Mukherjee et al., 2006; Okumura et al., 
2006; Schwer et al., 2006; Starai et al., 2002).  
For this reason we decided to perform immunoprecipitation-kinase assays from 
cells transfected with Flag-Cdk9 and increasing amounts of HA-GCN5 in order to 
induce Cdk9 acetylation. We found that GCN5 transfection impaired Cdk9 kinase 
activity on the GST-CTD substrate in a dose dependent manner (Figure 14A). This 
effect was clearly due to the acetyltransferase activity of GCN5 since the mutant 
HA-GCN5 (Y260A/F261A) that is HAT defective but still able to bind Cdk9 had no 
effect (Figure 14B). The same extracts used for the kinase assay were run on an 
SDS-PAGE gel and immunoblotted with an anti-Flag and anti-HA antibody to verify 
that GCN5 transfection did not modify Flag-Cdk9 expression. These results 
suggest that Cdk9 acetylation by GCN5  is inhibitory for its kinase activity.  
Since Cdk9 kinase activity is regulated by the interaction of the kinase with its 
cellular cofactors CyclinT1 (Peng et al., 1998; Peng et al., 1998) and HEXIM1 
(Michels et al., 2003; Yik et al., 2003), we wondered whether GCN5 transfection 
could modify these interactions. Therefore the same lysates used for the kinase 
assay were subject to immunoprecipitation with an anti-Flag antibody and then 
analyzed for the presence of co-precipitated endogenous CyclinT1 and HEXIM1. 
As reported in Figure 14C the amount of CyclinT1 and HEXIM1 co-precipitated with 
Flag-Cdk9 was the same in all lanes supporting the notion that acetylation affects 






Figure 14. GCN5 inhibits Cdk9 kinase activity. (A) Acetylation inhibits CDK9 
kinase activity. Flag-CDK9, immunoprecipitated from 293T cells transfected with 
the indicated plasmids, and recombinant GST-CTD, purified from bacteria, were 
incubated with [32P]-radiolabeled ATP and then resolved by SDS-PAGE followed 
by autoradiography. The graph shows the quantification of labeled GST-CTD in 
three independent experiments (mean±s.d.). The bottom two panels show protein 
expression levels. (B) Immunoprecipitation-kinase assay performed as in (A) from 




inactive (Y260A/F261A) mutant. (C) The same extracts as in (A) were subject to 
immunoprecipitation with an anti-Flag antibody and then analyzed by western blot 
for the presence of co-precipitated endogenous CyclinT1 and HEXIM1 proteins. 
 
Inhibition of Cdk9 kinase activity by GCN5 impairs Cdk9 function in 
transcription. 
Since acetylation inhibited the kinase activity of Cdk9 on RNAPII CTD in vitro, we 
analyzed whether this modification might affect the transcriptional regulation of 
Cdk9 responsive promoters inside the cells. For this purpose, we exploited the 
pG6(5’Pro) reporter system  that contained the HIV LTR linked to the CAT reporter 
gene. Six repeats of the synthetic Gal4-binding sites (UAS) were introduced 
upstream of the three Sp1 sites. These UAS repeats replaced the enhancer (EN) in 
the HIV LTR (Figure 15A).  Cdk9 alone, when tethered on this promoter by fusion 
to the  Gal4 DNA binding domain,  is able to induce transcription of the reporter 
gene (Taube et al., 2002). This allowed us to appreciate the effects of Cdk9 
acetylation in an in vivo system in a simplified, CyclinT1-independent manner. 
The pG6(5’Pro) reporter was transfected in  U2OS cells together with Gal4-Cdk9 
and increasing amounts of HA-GCN5, followed by the analysis of CAT production 
using an ELISA assay. We observed that promoter activation by Cdk9 was 
inhibited in a dose-dependent manner by the expression of enzymatically active 
GCN5, but not by its catalytically inactive variant (Figure 15B) 
In keeping with this result, when we used a siRNA against GCN5 to specifically 
inhibit endogenous GCN5 expression (as shown in the western blot of Figure 15C), 
we found that co-transfection of this siRNA (and not of an anti-Luciferase siRNA 
that we used as a negative control) together with the pG6(5’Pro) reporter and the 
Gal4-Cdk9 plasmid determined a remarkable increase of Cdk9-driven 
transcriptional activation (Figure 15C). 
In addiction, we verified that the non acetylable Cdk9 K44,48R mutant was 
insensible to GCN5 transfection. To perform this experiment, we exploited the 
capacity of Cdk9 to increase CyclinT1 transcriptional activity and co-transfected 
Gal4-CycT1 and the pG6(5’Pro) reporter with Flag-Cdk9 either wild type or 




activity but sufficient to indicate that it was  insensible to GCN5 overexpression, 
while wild type Flag-Cdk9 was inhibited by GCN5 (Figure 15D).  
 
Figure 15. GCN5 inhibits Cdk9-driven transcription. (A) Schematic 
representation of the pG6(5’Pro) reporter vector used for the transcription assays. 
(B) Acetylation inhibits CDK9 transcription activity. Extracts of U2OS cells 
transfected with the pG6(5’Pro) reporter together with the indicated plasmids were 
analyzed for CAT protein production by ELISA. The results are reported as 
percentage of CAT activity with respect to cells transfected with pG6(5’Pro) and 
Gal4-CDK9 alone; the graph summarizes the results obtained from three 
independent experiments (mean±s.d.). Expression of wt HA-GCN5 or its 




same experiment performed as in (B) was carried out by co-transfecting Gal4-
CDK9 together with 100 nM siRNAs against GCN5 or Luciferase; the bottom part 
of the panel reports western blottings for GCN5 and a-tubulin. (D) Extracts of 
U2OS cells transfected with the pG6(5’Pro) reporter together with the indicated 
plasmids were analyzed for CAT protein production by ELISA. The results are 
reported as percentage of CAT activity with respect to cells transfected with 
pG6(5’Pro) and Gal4-CyclinT1 alone; the graph summarizes the results obtained 
from three independent experiments (mean±s.d.). (E) The same experiment as in 
(B) was carried out by using Gal4-VP16 instead of Gal4-CDK9. 
 
In sharp contrast, expression of GCN5 had an opposite, activation effect when 
transcription was directed by the Gal4-VP16 transactivator (Figure 15E), as already 
described in the literature (Candau and Berger, 1996). 
Thus, the inhibition of Cdk9 transcriptional activity by enzymatically active GCN5 is 
consistent with the direct inhibition of Cdk9 kinase activity by acetylation. 
 
Acetylated Cdk9 accumulates at PML bodies 
Anti Ac-Cdk9 specific antibody detects endogenous acetylated Cdk9  
To better characterize acetylated Cdk9, we raised a specific antibody that 
recognizes this post-translationally modified form of Cdk9. We obtained a 15 amino 
acid peptide corresponding to Cdk9 (39-53) acetylated at positions 44 and 48. This 
peptide was coupled to KHL (Keyhole Limpet Hemocyanin) and used to immunize 
three rabbits. After some months sera were collected and the specificity of the 
antibody was tested in dot-blot experiments with increasing amounts of acetylated 
and not acetylated synthetic peptides as substrates. As shown in Figure 16A the 
serum specifically recognized the acetylated peptide and not the non acetylated 
one. Subsequently the IgG fraction was purified from the antiserum on columns 
bearing protein A. Purified anti-acetylated Cdk9 antibody was then tested by 
western blotting on immunoprecipitated wild type or K44,48R mutant Cdk9. Cdk9 
wild type or mutant were co-transfected with GCN5 (wild type or catalytically 






Figure 16. Characterization of anti Ac-CDK9 antibody. (A) Dot blot experiment 
showing specificity of the anti-acetylated CDK9 antibody. Fifteen-mer peptides 
corresponding to human CDK9 amino acids 39-53, either acetylated or not 
acetylated on lysines 44 and 48, were blotted onto nitrocellulose filters in the 
indicated amounts and challenged with IgGs (1:500) from an animal immunized 
with the acetylated peptide. The antibody clearly only recognizes the acetylated 
peptide. (B) Anti-Ac-CDK9 antibody specifically reacts with wild type CDK9 and not 
with the not acetylable CDK9 K44,48R  mutant. Extracts of 293T cells transfected 
with the indicated plasmids were immunoprecipitated with an anti-Flag antibody 
and subject to western blot (WB) with the anti-Ac-CDK9 or anti-Flag antibodies 
(upper two panels). Protein expression levels were verified by western blot on total 
cell lysates (lower three panels). WCL: whole cell lysate. (C) Anti-Ac-CDK9 
antibody is able to detect endogenous acetylated CDK9. TSA treated HeLa whole 
cell lysates (WCL) were subject to immunoprecipitation with the anti-Ac-CDK9 
antibody and then to immunoblotting with an anti-CDK9 antibody. Control IP was 




After SDS-PAGE and western blot the anti-AcCdk9 antibody recognized only wild 
type Flag-Cdk9 and not the non acetylable Flag-Cdk9 K44,48R even if the two 
proteins were immunoprecipitated at the same level (Figure 16B). The same 
extracts were run on an SDS-PAGE gel and immunoblotted with anti-Ac-Cdk9, 
anti-Flag and anti-HA antibody to verify protein expression levels. 
By using  this antibody we were able to detect endogenous acetylated Cdk9 inside 
the cells thus bypassing the sensitivity limits of standard anti-acetyllysine 
antibodies. As a matter of fact we could use this antibody to immunoprecipitate 
endogenous acetylated Cdk9 from HeLa cells treated with TSA and then we could 
detect it by western blot with an anti-Cdk9 monoclonal antibody (Figure 16C). 
 
Acetylated Cdk9 localizes in speckled structures inside the nucleus. 
The anti-Ac-Cdk9 antibody could also detect endogenous Cdk9 in 
immunofluorescence experiments.  
Total Cdk9 as well as transfected GFP-Cdk9 were found distributed throughout the 
nucleoplasm in both HeLa and U2OS cells, with lower levels of fluorescence also 
detectable in the cytoplasm, in accordance to published data (Napolitano et al., 
2002); Figure 17A.  In sharp contrast, acetylated Cdk9 was exclusively found in the 
nucleus, where it gave rise to a speckled pattern, indicative of distribution within 
specific subnuclear compartments (Figure 17B). The levels of acetylated protein 
within the Ac-Cdk9 foci increased upon cell treatment with the histone deacetylase 
inhibitor TSA. Of notice is the fact that the same treatment also determined the 
redistribution of transfected GFP-Cdk9 from its diffuse nucleoplasmic localization to 
form a punctuated pattern (Figure 17B).  
Since endogenous, transfected, and CFP-tagged GCN5 also showed a similar 
subnuclear distribution in a speckled pattern (Figure 17C), we tested whether 
GCN5 and acetylated Cdk9 co-localized within the same subnuclear structures. 
Figure 18 shows that a large fraction of GCN5 actually did co-localize with 
acetylated Cdk9 in the same speckled structures, and that the overall levels of 
acetylated Cdk9 were remarkably increased upon overexpression of wild type 





Figure 17. Acetylated Cdk9 and GCN5 have a speckled localization. (A) CDK9 
shows a diffuse localization inside the cells. Localization of transfected GFP-CDK9 
(left panels) and endogenous CDK9 (right panels) in HeLa and U2OS cells (where 
indicated). (B) Ac-CDK9  has a speckled nuclear localization. Localization of 
endogenous Ac-CDK9 by indirect immunofluorescence with the anti-Ac-CDK9 
antibody in HeLa cells mock treated (a) or treated with TSA (b); Localization of Ac-
CDK9 in cells transfected with Flag-CDK9 and treated with TSA (c); Localization of 
total GFP-CDK9 after cells treatment with TSA (d). (C) GCN5 accumulates in foci 
inside the nucleus. Immunofluorescence with an anti-GCN5 antibody to visualize 
endogenous (a) or transfected (b) GCN5; localization of overexpressed CFP-GCN5 
(c). 
 
The speckled distribution of acetylated Cdk9 and GCN5 is reminiscent of the 




correspond to the sites of accumulation of the promyelocytic leukemia protein 
(PML) (Marcello et al., 2003). These PML bodies represent subnuclear 
compartments in which several proteins variously involved in different cellular 
activities, including transcription, accumulate; most notably, these are sites in 
which post-translational modification of many proteins occurs (for reviews, see: 
(Zhong et al., 2000)), as detailed in the Introduction. Thus we decided to further 
investigate the relationship between acetylation of Cdk9 and PML. 
 
 
Figure 18. Co-localization of Ac-CDK9 and GCN5 in speckled structures. 
Transfection  of enzymatically active GCN5, but not of its catalytically inactive 
variant, increases the amount of Ac-CDK9 inside the cells. Double 




with wt or catalytically inactive HA-GCN5) in cells transfected with the indicated 
plasmids. Expression of enzymatically active GCN5 dramatically increases the 
levels of Ac-CDK9 in nuclear speckles, which are lower in untransfected cells 
(arrows) or cells expressing the catalytically inactive GCN5 mutant. 
 
Cdk9 interacts with PML  
First we wanted to asses whether total Cdk9 localizes inside PML bodies like its 
cyclin partner. For this reason we transfected cells with Cdk9 and/or PML-IV 
expressing vectors and then analyzed the localization of these proteins by 
immunofluorescence experiments.  
We found that at the endogenous level of PML, Cdk9  showed a diffuse localization 
even when it was overexpressed as GFP-Cdk9 (Figure 19A first row) or Flag-Cdk9 
(Figure 19B first and second rows). Nevertheless, after transfection of PML-IV (but 
not of PMLRARa), Cdk9 (both endogenous and transfected) assumed a speckled 
distribution that co-localized with  PML bodies, thus demonstrating an affinity 
towards this subnuclear compartment (Figure 19A second and third row, Figure 
19B third and fourth rows). 
In order to understand whether the observed re-localization of Cdk9 was mediated 
by an interaction between Cdk9 and the PML protein we performed an in vitro 
binding assay between GST-PML-IV and [35S]-labeled Cdk9. GST-PML-IV 
immobilized on beads was incubated with [35S]-Cdk9; the beads were then 
extensively washed and the proteins resolved by SDS-PAGE. Figure 20B shows 
the gel stained with Coomassie blue (lower panel) and after autoradiography 
(upper panel). Labeled Cdk9 was found to bind to GST-PML-IV but not to GST 
alone. 
This interaction was confirmed also in vivo by co-immunoprecipitations 
experiments. Flag-Cdk9 was transfected in 293T cells alone or together with PML-
IV, then Cdk9 was immunoprecipitated with an anti-Flag antibody and the 
complexes analyzed by western blot with an anti-PML antibody. PML was found to 
specifically co-precipitate with Cdk9 when overexpressed, but not at the 






Figure 19. Cdk9 and PML co-localize inside PML bodies. (A) GFP-CDK9 co-
localizes with PML when PML-IV is overexpressed. (B) Endogenous and Flag-
CDK9 co-localize with PML when PML-IV is overexpressed. U2OS cells were 
transfected with indicated plasmids and subject to immunofluorescence with anti-
PML antibody (A) or to double immunofluorescence with antibodies against PML 





Figure 20. Cdk9 interacts with PML in vivo and in vitro. (A) CDK9 binds PML-IV 
in vitro. GST-PML-IV or GST alone as a control were incubated with [35S]-CDK9, 
extensively washed and then analyzed by SDS-PAGE. The upper panel shows the 
gel exposed to a phosphoimager screen, while the lower panel the Coomassie 
stainings of the same gels. (B) CDK9 binds PML-IV in vivo. Extracts prepared from 




antibody and immunoblotted with anti-PML antibody.  The same extracts were run 
on an SDS-PAGE gel and immunoblotted with anti-PML and anti-Flag antibodies to 
verify protein expression levels (lower two panels). (C) CDK9 binds the coiled coil 
domain of PML in vitro. GST-CDK9 or GST alone as a control were incubated with 
[35S]-labeled PML isoforms or mutants, extensively washed and then analyzed by 
SDS-PAGE. The upper panels show the gel exposed to a phosphoimager screen, 
while the lower panel the Coomassie stainings of one representative gel. 
 
In order to investigate whether the interaction between Cdk9 and PML is isoform 
specific or common to all PML proteins, besides PML-IV, we analyzed the 
interaction of Cdk9 also with the PML-III isoform and with the oncogenic form 
PMLRARa. These three PML variants, which differ in their C-termini but maintain 
an intact RBCC motif, were all capable of binding Cdk9 in vitro (Figure 20D), 
suggesting that the interaction domain lies within the RBCC region. We also 
assayed a deletion mutant of PML-III, PMLΔ(216-333), lacking the coiled-coil 
domain, and another mutant, PML A3 RING, with a non-functional RING domain. 
While the latter behaved like the wild-type protein, the mutant in the coiled-coil 
domain lost its ability to associate with Cdk9 (Figure 20D). This experiment 
demonstrated that the association of Cdk9 with PML is not limited to a subset of 
PML isoforms and requires an intact coiled-coil domain. 
 
 
Figure 21. PML inhibits Cdk9-mediated transcription. Extracts of U2OS cells 
transfected with the pG6(5’Pro) reporter together with the indicated plasmids were 




percentage of CAT activity with respect to cells transfected with pG6(5’Pro) and 
Gal4-CDK9 alone; the graph summarizes the results obtained from three 
independent experiments (mean±s.d.). Expression of PML and Gal4-CDK9 was 
verified by western blot (lower panels). 
 
 
Figure 22. HEXIM1 co-localizes with PML when PML is overexpressed. (A) 
Immunofluorescence of endogenous HEXIM1 in U2OS cells transfected with GFP-
CyclinT1. (B) Immunofluorescence of endogenous HEXIM1 in U2OS cells 
transfected with GFP-PML-IV. (C) Double immunofluorescence with antibodies 




Accumulation of CyclinT1 in PML bodies correlated with inhibition of P-TEFb 
transcription at the HIV-1 promoter, thus we wondered which was the effect of PML 
on Cdk9-dependent transcription. For this purpose, we exploited the pG6(5’Pro) 
reporter system  that, as previously described, could be activated by Gal-Cdk9 in a 
CyclinT1 independent manner. We found that PML-IV transfection inhibited Gal4-
Cdk9 transcription activity in a dose dependent manner with an efficacy similar to 
that observed for GCN5 (Figure 21). 
Since one of the best characterized inhibitors of P-TEFb is the HEXIM1 protein 
(Michels et al., 2003; Yik et al., 2003), we wondered whether accumulation of Cdk9 
within PML bodies increased its association with HEXIM1.  
First we analyzed the subcellular localization of HEXIM1 in order to see whether it 
can be found at PML bodies. Endogenous HEXIM1 showed a diffuse localization 
inside the nucleus even in case of GFP-CyclinT1 (Figure 22A) or GFP-PML-IV 
(Figure 22B) transfection. Nevertheless when overexpressed as Flag-HEXIM1, it 
re-localized into PML bodies upon PML overexpression (Figure 22C second row) 
and more efficiently upon PML plus CyclinT1 co-transfection (Figure 22C third 
row), thus supporting the notion that PML might facilitate the binding between Cdk9 
and HEXIM1 by recruiting both proteins in the same compartment. Anyway, 
HEXIM1 localization at PML bodies was not observed at endogenous levels of 
HEXIM (even in case of PML-IV transfection), and was only partial also in case of 
Flag-HEXIM1 transfection if CyclinT1 was not co-transfected together with PML-IV. 
Furthermore we found that PML transfection did not change the interaction 
between Cdk9 and HEXIM1 or CyclinT1. 293T cells were transfected with Flag-
Cdk9 and increasing amounts of pcDNA3-PML-IV, then Flag-Cdk9 was 
immunoprecipitated with an anti-Flag antibody and bound proteins were analyzed 
by SDS-PAGE and western blot with CyclinT1 (Figure 23A) or HEXIM1 (Figure 
23B) antibodies. These experiments revealed that Flag-Cdk9 co-
immunoprecipitated the same amount of CyclinT1 or HEXIM1 protein in presence 
or in absence of PML-IV overexpression. 
These results open the possibility that another mechanism, possibly based on 






Figure 23. PML does not modify the interaction between CDK9 and its 
regulatory partners. 293T cells transfected with Flag-CDK9 and increasing 
amounts of PML-IV were subject to immunoprecipitation with an anti-Flag antibody 
and then analyzed by western blot for the presence of co-precipitated endogenous 
CyclinT1 (A) and HEXIM1 proteins (B). Protein expression was verified by western 
blot on total cell lysates. 
 
Acetylation increases Cdk9 affinity for PML bodies  
The localization of endogenous PML was remarkably different from that of total 
Cdk9 (which is mainly not acetylated), unless PML was overexpressed (Figure 
24A). In contrast, a remarkable proportion of endogenous acetylated Cdk9 
localized within endogenous PML bodies, and overexpression of PML or PML plus 
GCN5 markedly enhanced this localization (Figure 24B), suggesting that 





Figure 24. Acetylated CDK9 co-localizes with PML in PML bodies. (A) Most 
endogenous CDK9 does not co-localize with endogenous PML (upper panel); 
however, overexpression of PML-IV forces redistribution of endogenous CDK9 to 
nuclear bodies (lower panels). (B) Ac-CDK9 co-localizes with both endogenous or 
transfected PML in nuclear bodies.  In (A) and (B) U2OS cells were transfected 
with indicated plasmids and subjected to double immunofluorescence with 
antibodies against PML and CDK9 or Ac-CDK9 respectively. 
 
PML bodies are known to associate with the insoluble nuclear matrix fraction after 
biochemical fractionation (Fogal et al., 2000). We therefore fractionated total 
extracts from cells that were transfected with Cdk9 and GCN5 in order to enhance 




was extracted by lysis in high salt buffer containing NP-40. The same amounts of 
proteins for each fraction were separated by SDS-PAGE and analyzed by western 
blot with specific antibodies. Under this conditions,  PML-IV was found within  the 
insoluble matrix fraction, while total Cdk9 partitioned in the soluble and insoluble 
nuclear fractions, as well as in the cytoplasmic fraction. In contrast, acetylated 
Cdk9 was almost exclusively present in the insoluble nuclear matrix fraction, 
together with transfected GCN5 and PML (Figure 25A).  
 
Figure 25. Ac-CDK9 localizes in the nuclear matrix fraction together with PML 
and GCN5.(A) Ac-CDK9 fractionates in the insoluble nuclear fraction together with 
PML. Extracts of 293T cells transfected with Flag-CDK9 and HA-GCN5 were 
separated into cytosolic, nuclear soluble and nuclear insoluble fractions as 
described in Materials and Methods. The same amounts of proteins for each 
fraction were separated by SDS-PAGE and analyzed by western blot with specific 
antibodies. As a control of fractionation,  PML localization in the insoluble fraction 
was verified. (B) Both GCN5 and PML force re-localization of total CDK9 into the 
insoluble nuclear fraction. Nuclear extracts of 293T cells transfected with the 
indicated plasmids were separated into a soluble and insoluble fraction. 
Comparable amounts of proteins for each fraction were separated by SDS-PAGE 
and analyzed by western blot with an anti-Flag antibody. The amount of Flag-
protein in each fraction was then quantified by densitometric analysis. The graph 




Nevertheless the insoluble fraction of Flag-Cdk9 was more abundant of what we 
could expect from the diffuse localization that Cdk9 showed in absence of PML 
transfection. This could be explained by the fact that in the biochemical 
fractionation assay the cells were co-transfected with HA-GCN5 and, as we can 
see in Figure 25A, also this protein partitioned in the insoluble nuclear matrix 
fraction like PML. Therefore GCN5 transfection could have partially re-localized 
Flag-Cdk9 in the insoluble fraction. In fact,  we observed that, upon transfection of 
GCN5, PML or both these proteins, the fraction of insoluble Cdk9 raised from 40% 
to 62, 59 and 76% respectively, clearly indicating that the expression of both PML 
and GCN5 causes significant re-localization of Cdk9 toward matrix-associated 
structures (Figure 25B). 
 
Figure 26. Ac-Cdk9 preferentially binds PML. (A) 293T cells transfected with 
Flag-CDK9, PML-IV and HA-GCN5 were subject to immunoprecipitation with an 




western blot with anti-Flag, anti-Ac-CDK9 and anti-PML antibodies. The amount of 
bound proteins respect to input was quantified by densitometric analysis. The 
graph shows the results obtained in three independent experiments (mean±s.d.). 
(B) PML immuno-depletion preferentially removes Ac-CDK9 from cell extracts. 
Extracts of 293T cells transfected with indicated plasmids  were passed through 
anti-Flag antibody beads or control protein A beads five times. Flag-PML-IV, Ac-
CDK9, CDK9, HA-GCN5 and Tubulin protein expression after depletion was 
verified by western blot using specific antibodies and then quantified by 
densitometric analysis. The graph shows the results obtained in three independent 
experiments (mean±s.d.). 
 
The specific interaction between Ac-Cdk9 and PML was further demonstrated by 
co-immunoprecipitation assays. Cells were transfected with PML-IV, Flag-Cdk9 
and HA-GCN5 and then subject to immunoprecipitation with an anti-PML antibody 
or an irrelevant antibody as a control. After SDS-PAGE and western blot with anti-
Cdk9 and anti-Ac-Cdk9 antibodies, the amount of bound proteins respect to input 
was assessed  by densitometric analysis and we found that Ac-Cdk9 co-
precipitated with PML more efficiently than total Cdk9 (Figure 26A).  
The relative amount of acetylated Cdk9 which was bound to PML was assessed by 
immunodepletion experiments. After transfection with Flag-PML-IV, Cdk9 and 
GCN5, cell extracts were passed through anti-Flag antibody beads 5 times, which 
almost completely removed Flag-PML from the extracts. Strikingly, depletion of 
PML led to the selective removal of more than 80% of acetylated Cdk9, compared 
to about 15% of total Cdk9 (which also includes the acetylated portion); Figure 
26B. These results further strengthen the notion that acetylated Cdk9 selectively 
accumulates at PML bodies. 
 
Cdk9 localization at PML bodies is independent from acetylation 
Whether acetylation of Cdk9 might be the consequence or the cause of the re-
localization in PML bodies still remains to be completely determined. However, we 
have clues that Cdk9 K44,48R mutant still re-localizes at PML bodies upon PML-IV 
overexpression, favoring a model by which acetylation is not requires for Cdk9 





Figure 27. CDK9 K44,48R interacts with PML. (A) U2OS cells were transfected 
with Flag-CDK9 wild type or K44,48R together with PML-IV and subject to 
immunofluorescence with anti-Flag antibodies. (B) 293T cells were transfected with 
indicated plasmids and subject to immunoprecipitation with anti-Flag antibodies. 
Proteins in the bound fraction were analyzed with anti-PML and anti-Flag 
antibodies. (C) Extracts of 293T cells transfected with indicated plasmids were 
separated into cytosolic, nuclear soluble and nuclear insoluble fractions as 
described in Materials and Methods. The same amounts of proteins for each 






After co-transfection of Flag-Cdk9 K44,48R and PML-IV in U2OS cells, 
immunofluorescence analysis with an anti-Flag antibody revealed that mutant Cdk9 
had no longer the nucleo-cytoplasmic distribution previously described, but 
accumulated at PML bodies like wild type Flag-Cdk9 (Figure 27A).  
This localization suggested that Cdk9 K44,48R could still bind the PML protein. In 
order to verify this finding, we transfected 293T cells with Flag-Cdk9, either wild 
type or mutated, together with PML-IV, then after immunoprecipitation with anti-
Flag antibodies bound proteins were analyzed by western blot with anti-PML 
antibodies. Flag-Cdk9 K44,48R co-immunoprecipitated with transfected PML-IV 
with an efficacy similar to wild type Cdk9 (Figure 27B). 
Finally we found that, besides wild type Cdk9, also K44,48R Cdk9 could be 
partially re-localized into the insoluble nuclear matrix fraction upon transfection of 
both wild type GCN5 or its catalytically inactive mutant (Figure 27C).  
These results suggest that the interaction between Cdk9 and GCN5 (which, as 
already shown, is independent from the HAT activity of GCN5), and not Cdk9 
acetylation,  targets Cdk9 to PML bodies. There, GCN5-mediated acetylation of the 
catalytic pocket of Cdk9 might ensure inhibition of  P-TEFb activity and, at the 
same, time sequestration in the nuclear bodies compartment. 
 
GCN5 interacts with PML  
The idea that GCN5 might target Cdk9 to PML bodies is further supported by the 
fact that GCN5 itself, like other cellular HATs, such as p300 and CBP (Marcello et 
al., 2003; von Mikecz et al., 2000),  interacts with the PML protein  
We found that transfected GCN5 co-fractionated with PML in the insoluble nuclear 
matrix (Figure 25A) and that PML immunodepletion removed a high percentage of 
GCN5 from cell extracts (Figure 26B). Having therefore observed that GCN5 had a 
speckled distribution within the nucleus (Figure 17C), we wondered whether the 
compartments in which it resides has any relationship with PML bodies. For this 
purpose we transfected cells with either HA-GCN5 or PML-IV expressing vectors or 







Figure 28. GCN5 interacts with PML. (A) GCN5 co-localizes with PML. U2OS 
cells were transfected with indicated plasmids and subject to double 
immunofluorescence with antibodies against GCN5 and PML. (B) GCN5 binds 
PML-IV in vivo. Extracts prepared from cells transfected with indicated plasmids 
were immunoprecipitated with an anti-Flag antibody and immunoblotted with anti-




immunoblotted with anti-HA and anti-Flag antibodies to verify protein expression 
levels (lower two panels). 
 
We found that endogenous GCN5 localized in many small foci inside the nucleus, 
whereas transfected GCN5 became more diffuse in the nucleus but still 
accumulates in few larger foci. In both situations, GCN5 foci partially co-localized 
with PML bodies (Figure 28A, first and third rows). This co-localization increased 
after transfection of PML-IV (Figure 28A second row) and became almost complete 
when HA-GCN5 and PML-IV were both transfected (Figure 28A fourth row). 
The interaction between GCN5 and PML was confirmed by co-
immunoprecipitations experiments. Flag tagged PML-IV was expressed in 293T 
cells together with HA-GCN5, followed by immunoprecipitation using an anti-Flag 
antibody and immunoblotting with an anti-HA antibody. As shown in the upper 
panel of Figure 28B, HA-GCN5 specifically co-precipitated with Flag-PML-IV, but 
not with the control pFlag empty vector. The same extracts were run on an SDS-
PAGE gel and immunoblotted with an anti-Flag and anti-HA antibody to verify 
protein expression levels. 
From this set of experiments we concluded that GCN5 interacts with PML in vivo 
inside nuclear bodies.  
In conclusion, we have found that Cdk9 can be targeted to PML bodies 
independently from its acetylation, that GCN5 can localize at PML bodies and that 
both acetylation and accumulation at PML bodies inhibit Cdk9 transcription.  
 
Selective binding of acetylated Cdk9 to the HIV-1 promoter and 
HIV-1 genome during transcriptional latency 
In order to understand the physiological relevance of Cdk9 acetylation, we 
exploited HIV-1 transcription as a model system that is highly dependent on Cdk9 
kinase activity. In fact, the activation of the HIV-1 long terminal repeat  (LTR) 
promoter by the viral transactivator Tat is blocked by concentrations of P-TEFb 
inhibitors that do not affect regular cellular transcription (Chao et al., 2000; Chao 




In particular we focused on the regulation of HIV-1 latency by exploiting  the U1 
monocytic cell line, a well defined model of post-integration latency (Lusic et al., 
2003). This cell line contains two copies of the integrated provirus, which, under 
basal conditions, produce almost undetectable levels of HIV-1 mRNA; transcription 
is markedly induced (over 100 fold) by exposure to different mitogens, including 
phorbol esters (TPA);Figure 29A.  
To determine whether transcriptional activation by TPA induces a modification of 
Cdk9 acetylation in vivo at the HIV-1 genome, aliquots of untreated and TPA-
treated U1 cells were analyzed in parallel by chromatin immunoprecipitation 
(ChIP). Formaldehyde crosslinked, sonicated chromatin fragments from U1 cells 
were immunoprecipitated using antibodies directed against RNAPII, Ser2P-
RNAPII, total Cdk9 and Ac-Cdk9.  
Six different genomic sites were investigated. One region (B13) maps on 
chromosome 19, 5 kb away from the lamin B2 origin in a region not containing any 
gene and therefore used here as a negative control  (Todorovic et al., 2005); while 
the other five map to contiguous regions in the HIV-1 proviral DNA: two in the 
promoter (PPR and Nuc-1A), and three in the coding region at the 5' end of the 
genome (U1A, U1B and U1C); Figure 29B. 
In particular the two regions on the HIV-1 promoter have been chosen because 
they have been extensively studied in relation to the transcriptional state of HIV-1. 
Experiments performed both in vivo (El Kharroubi et al., 1998; Van Lint et al., 1996; 
Verdin et al., 1993) and in vitro (Sheridan et al., 1997; Van Lint et al., 1996) using 
the HIV-1 promoter reconstituted into chromatin have shown that, independent 
from the integration site, nucleosomes at the 5’ LTR are precisely positioned with 
respect to cis-acting regulatory elements and define two large nucleosome-free 
areas. The first one (PPR) is composed of the core promoter, containing three 
tandem Sp-1 binding sites and the TATA box sequence, and of the LTR enhancer, 
which is the target for the p50/p65 NF-kB heterodimer; the same region also 
contains the binding sites for other transcription factors including Ets-1 and USF. 
The second open area spans the primer-binding site immediately downstream of 
the 5’ LTR. These two open regions are separated by a single nucleosome called 




and is  specifically and rapidly destabilized during transcriptional activation (El 
Kharroubi et al., 1998; Van Lint et al., 1996; Verdin et al., 1993). We decided to 
extend our ChIP analysis also to the three regions inside the HIV-1 genome 
because, as described in the Introduction, Cdk9 activity is required not only at 
promoters but also within coding regions. 
In uninduced conditions, RNAPII was present on the promoter region but not inside 
the HIV-1 genome (Figure 29C); most of this polymerase was not phosphorylated 
on Ser2 (Figure 29D). Following TPA induction, the levels of both total RNAPII and 
Ser2-phosphorylated RNAPII increased on the promoter region; of interest, Ser2P 
RNAPII was also found distributed inside the proviral genome (Fig. 21C and D). 
Phosphorylation of RNAPII Ser2 is known to be essentially catalyzed by Cdk9 (Ni 
et al., 2004; Shim et al., 2002). Consistent with this notion, the levels of Cdk9 
associated with both the promoter and the proviral genome were significantly 
increased upon TPA induction, thus paralleling those of RNAPII Ser2P (Figure 
29E). Most strikingly, by using the specific anti-Ac-Cdk9 antibody, we observed 
that, in uninduced cells, a large amount of catalytically inactive, acetylated Cdk9 
was associated with both the HIV-1 promoter and the HIV-1 genome; acetylated 
Cdk9 was absent from both regions after TPA stimulation (Figure 29F). Thus, the 
latent state of HIV-1 is characterized by the recruitment of low levels of RNAPII 
within the promoter region; this polymerase is not phosphorylated on Ser2 since 
Cdk9 is kept in an enzymatically inactive state by acetylation. Transcriptional 
activation is concomitant with an increase in the total levels of recruited Cdk9 and, 
most notably, in a marked reduction of its acetylated form. These results clearly 
indicate that acetylation of Cdk9 essentially concurs in maintaining transcriptional 






Figure 29. Ac-CDK9 selectively binds HIV-1 genome during transcriptional 
latency. (A) Induction of HIV-1 transcription in U1 cells after TPA stimulation. The 
levels of HIV-1 mRNA were measured by real time PCR using TaqMan primers 
and probe corresponding to the Nuc1A region – see panel b; the results are 
expressed as a ratio between HIV-1 mRNA and the cellular 18S rRNA. (B) 




of the LTR, including the transcription start site, is indicated, along with the known 
nucleosomal arrangement at the 5' genome region. (C-F) Chromatin 
immunoprecipitation experiments using antibodies against total RNAPII, RNAPII 
CTD phosphorylated on serine 2 (RNAPII-Ser2P), total CDK9 and acetylated 
CDK9 in latent and TPA-activated U1 cells. For each analyzed region, the amount 
of immunoprecipitated chromatin using the indicated antibodies is shown, 















One of the essential molecular events that regulate gene expression in eukaryotic 
cells is the phosphorylation of the carboxy-terminal domain (CTD) of RNA 
polymerase II (RNAPII), which is required for efficient promoter clearance and 
transcriptional processivity (Meinhart et al., 2005). Among the different members of 
the cyclin-dependent kinase family that are known to specifically induce this 
modification, the P-TEFb complex is mainly responsible for the phosphorylation of 
Ser2 of CTD, an event representing the hallmark of elongating RNAPII.  
Studies performed by using either RNA interference or highly specific inhibitors 
have indicated that P-TEFb acts as a global co-factor important for most RNAPII 
transcription (Chao and Price, 2001; Shim et al., 2002). Not surprisingly, therefore, 
its activity appears to be tightly regulated in different cell types, along differentiation 
and as part of the cell response to various stimuli (Sano et al., 2002; Yang et al., 
1997; Zhou et al., 2000). To achieve this goal, different features of its components, 
Cdk9 and CyclinT1, are controlled: level of expression, interaction with other 
proteins, post-translational modifications (i.e. phosphorylation and ubiquitination) 
and subcellular localization.   
 
Acetylation modifies crucial residues of Cdk9 
The work described in this thesis reveals a new mechanism of regulation of P-
TEFb that involves both post-translational modification and subcellular localization.  
First of all, we demonstrated for the first time that Cdk9 is acetylated in vitro and in 
vivo by the GCN5 acetyltransferase. Interestingly, the acetylated lysines of Cdk9 lie 
in close proximity to the PITALRE amino acid sequence (position 60-66). This 
region is essentially involved in the formation of the catalytic pocket of Cdk9, and 
its sequence is highly conserved in all members of the Cdk family (as shown in 
Figure 13A). Moreover, one of the two acetylated lysines (K48) is conserved in the 
so-called subdomain II of almost all the eukaryotic protein kinases (conserved in 
over 95% of 370 sequences), and hence  essential for the enzyme function (Hanks 
and Hunter, 1995). Consistent with this notion, conservative mutations of Cdk9 




Structural data about Cdk2 indicate that the conserved subdomain II lysine is 
essentially involved in orienting the ATP phosphate residues as well as in 
magnesium binding within the catalytic pocket of the enzyme (De Bondt et al., 
1993).  
 
Figure 30. CDK2 catalytic pocket. Adapted from (Pavletich, 1999) . 
 
Not surprisingly, we found that the mutant Cdk9 K44,48R had reduced affinity for 
the ATP analog, FSBA. FSBA was previously used to map the ATP-binding sites of 
various proteins, including PKA and smooth muscle myosin light chain kinase 
(Komatsu and Ikebe, 1993; Zoller et al., 1981). The FSBA reactive residues were 
subsequently shown to play crucial roles in the phosphotransfer reaction 
(Madhusudan et al., 1994; Taylor et al., 1992). As a matter of fact FSBA contains a 
crosslinking group in the position analogous to the g-phosphate of ATP (Kamps et 
al., 1984), the transfer and correct positioning of which are probably regulated by 
the conserved lysine of subdomain II of protein kinases.  
In both types of experiments (kinase assay and FSBA binding) the mutant Cdk9 
K44,48R maintains a residual activity, while we expected a complete loss of 
activity. We have still to consider that we introduced a conservative mutation of 
lysines to arginines while a mutation to alanines would probably have had more 
profound effects. In keeping with this notion, the K-R mutation in human 
sphingosine kinase 1 reduced the enzymatic activity to 30%, while the K-A 




mind that even if the subdomain II lysine is very important for the kinase activity, 
there could be other lysines that might compensate for it. Two examples of 
situations in which this event occurs are the catalytic subunit of S. cerevisiae cAMP 
dependent protein kinase (Gibbs and Zoller, 1991) and the large subunit of herpes 
simplex virus type 2 of ribonucleotide reductase (ICP10) (Nelson et al., 1996). 
 
Acetylation inhibits Cdk9 kinase activity 
As described in the Introduction, acetylation has been reported to modulate DNA 
binding (Gu and Roeder, 1997; Marzio et al., 2000; Yao et al., 2001), protein-
protein interactions (Bannister et al., 2000; Cohen et al., 2004; Kovacs et al., 2005; 
Yuan et al., 2005), protein stability (Bernassola et al., 2004; Jeong et al., 2002; Li 
et al., 2002) and  subcellular localization (Blander et al., 2002; Kawaguchi et al., 
2006; Kitamura et al., 2005; Thevenet et al., 2004) and the consequence of 
acetylation on protein function may vary from one protein to another depending on 
where within the protein the acetylation takes place. 
Since acetylation neutralizes the positive charge of the ε-amino group of lysines 
that are positioned in the catalytic pocket of Cdk9 and are involved in ATP binding, 
it was not surprising to find that overexpression of GCN5 (and the subsequent 
increased acetylation of Cdk9) inhibited P-TEFb kinase activity on the RNAPII 
CTD. 
This is not the first case of acetylation occurring on residues that lie in the catalytic 
site of an enzyme: acetylation of a lysine positioned in the catalytic center of 
Acetyl-CoA synthetase inhibits its enzymatic activity both in S. enterica (Starai et 
al., 2002) and in mammals (Hallows et al., 2006; Schwer et al., 2006), similar to 
what also happens in the PTEN phosphatase (Okumura et al., 2006). Yersinia 
YopJ acetylates serines and threonines in the activation loop of MAPKK6 thereby 
blocking their phosphorylation and the activation of the kinase (Mukherjee et al., 
2006).  
Anyway, Cdk9 is the first example of regulation of a Cdk by acetylation and the 
observation that one of the lysines that becomes acetylated in Cdk9 is strictly 




might play a broader role in controlling the function of other members of this kinase 
family. As a matter of fact preliminary observations in our laboratory indicate that 
some Cdks involved in cell cycle control are indeed acetylated by GCN5. These 
findings may open a new field of investigation, since GCN5 appears to be involved 
in the control of many cell-cycle related genes (Kikuchi et al., 2005). 
 
Acetylation does not impair the binding of Cdk9 to its regulatory 
partners 
Even if acetylation of Cdk9 modifies the catalytic site of the enzyme, it does not 
seem to affect its interaction with CyclinT1 and HEXIM1. As a matter of fact the 
amount of CyclinT1 and HEXIM1 co-precipitated with Flag-Cdk9 did not change 
upon GCN5 overexpression, supporting the notion that acetylation affects Cdk9 
catalytic activity rather than modulating interaction with its known regulatory 
partners. 
Regarding this point, it is worth mentioning that the catalytic pocket of Cdks, inside 
which Cdk9 acetylated lysines reside, is completely folded only after the binding to 
the cyclin partner (Pavletich, 1999).  Cdks activation has been understood in 
structural detail from X-ray crystallographic studies of human Cdk2 in various 
states of activity.  
The active site of Cdk2 is located in a cleft between two lobes of the kinase. ATP 
binds deep within the cleft, with its phosphates oriented outward. The protein 
substrate would normally interact with the entrance of the active-site cleft, but this 
region is obscured in the inactive Cdk2 monomer by the T-loop. Key residues in the 
ATP-binding site are also misoriented in the Cdk2 monomer, further suppressing its 
activity (Figure 31A). Cyclin A binding has a major impact on the conformation of 
the Cdk2 active site (Figure 31B). Several helices in the cyclin box contact both 
lobes of Cdk2 in the region adjacent to the active-site cleft, resulting in extensive 
conformational changes in Cdk2. 
The most obvious change occurs in the T-loop, in which the L12 helix has been 
changed into a beta strand, and which no longer occludes the binding site for the 




occur in the ATP-binding site, leading to the correct positioning of the ATP 
phosphates for the phosphotransfer reaction.  
 
 
Figure 31. The structural basis of Cdk activation. These diagrams illustrate the 




structure is represented in the left column, while the right column provides 
schematic views that emphasize key substructures, including the ATP in the active 
site, the T-loop (green) and the PSTAIRE helix (red).  
 
The T-loop of Cdk2 contains Thr 160, the threonine residue whose phosphorylation 
by the Cdk-activating kinase (CAK) further increases the activity of the Cyclin A–
Cdk2 complex. After phosphorylation, the phosphate on Thr 160 is inserted in a 
cationic pocket and acts as the central node for a network of hydrogen bonds 
spreading outward to stabilize neighbouring interactions in both the Cdk and 
Cyclin. The T-loop is flattened and moves closer to Cyclin A (Figure 31C), and this 
region serves as a key part of the binding site for protein substrates (Figure 31D).  
This data indicate that the conserved lysine in the catalytic cleft of Cdks, namely 
K48 for Cdk9, is partially occluded by the T-loop until the cyclin has bound the 
kinase, as shown in Figure 32. Therefore, CyclinT1 binding (and maybe also T-loop 
phosphorylation) might be necessary in order to completely expose the K48 
residue of Cdk9 to GCN5-mediated acetylation.  
 
 
Figure 32. Close-up views of Cdk2 T loop, before and after Cyclin A binding. The T 
loop of Cyclin A-bound Cdk2 is highlighted in yellow while that of free Cdk2 is 
green. Thr160, which is phosphorylated by CAK, is colored red (Pavletich, 1999). 
 
The fact that CyclinT1 binds Cdk9 also in case of GCN5 transfection (and thus 
Cdk9 iper-acetylation), together with these structural data, suggest that acetylation 




Additional biochemical experiments are required to further characterize the 
relationship between Cdk9 folding and acetylation.  
We have not tested the effect of Cdk9 acetylation on the binding to Brd4 that has a 
bromodomain and therefore could be a good candidate for increased interaction 
after acetylation, since in vitro binding experiments indicated that actually Brd4 
binds CyclinT1 and not Cdk9 (Jang et al., 2005). Interestingly, Cyclin T1 has been 
recently found in a proteomic search of acetylated proteins (Kim et al., 2006) 
therefore we can speculate that acetylation of CyclinT1, in contrast to that of Cdk9,  
has an activating effect on P-TEFb activity increasing the binding to the positive 
factor Brd4. 
 
Acetylation re-localizes Cdk9 at PML bodies 
We demonstrated that Cdk9, like its main cyclin partner Cyclin T1, accumulates at 
nuclear bodies upon PML overexpression through direct interaction with the PML 
protein. 
Despite the attention paid to these structures, the function of PML bodies is still not 
fully known. One of the proposed role for PML bodies is to be sites of post-
translational modification and degradation of proteins. Observations supporting this 
model include the acetylation (Pearson et al., 2000), phosphorylation (D'Orazi et 
al., 2002) and sumoylation (Fogal et al., 2000; Kwek et al., 2001) of p53 at PML 
bodies and the localization of ubiquitin/proteasome associated proteins at some 
PML bodies (Anton et al., 1999; Everett et al., 1997; Lafarga et al., 2002; 
Lallemand-Breitenbach et al., 2001).  
Acetylated Cdk9 co-localizes and co-precipitated with PML to a higher extent in 
comparison with total Cdk9 (mostly not acetylated) indicating that Cdk9 acetylation 
increases its affinity towards the PML bodies compartment. Whether acetylation of 
Cdk9 might be the consequence or the cause of the re-localization in PML bodies 
still remains to be completely determined since  we have not rule out whether PML 
promotes Cdk9 acetylation like it does with p53 (Pearson et al., 2000) and p73 




However, these data suggests that acetylation actually occurs preferentially inside  
PML bodies: 
∑ Cdk9 K44,48R mutant re-localizes at PML bodies upon PML-IV 
overexpression even if it cannot be acetylated; 
∑ both wild type and K44,48R Cdk9 can be re-localized in the nuclear matrix 
fraction by GCN5 catalytically active or inactive; 
∑ GCN5, like other cellular acetyltransferases,  localizes at PML bodies. 
Thus we hypothesized that the interaction with either GCN5 or PML protein may 
target Cdk9 to PML bodies; then if Cdk9 is acetylated by GCN5, this modification 
strengthens the binding between Cdk9 and PML and entraps Cdk9 in the nuclear 
matrix compartment probably in a  transcriptionally silent context.  In keeping with 
this model, our laboratory has previously described the inhibitory effect of 
accumulation in PML bodies for CyclinT1 mediated transcription (Marcello et al., 
2003). Other examples of proteins that are targeted at PML bodies upon 
acetylation are the transcription factor FoxO1 (Kitamura et al., 2005) and the DNA 
helicase Werner (Blander et al., 2002). 
Indeed PML bodies have been proposed to be a regulated nuclear depot  where 
proteins such as co-activators, co-repressors or transcription factors are 
accumulated and released upon specific signals (Li and Chen, 2000; Negorev and 
Maul, 2001; Zhong et al., 2000). By titrating these factors from the active pool in 
the nucleoplasm, the PODs could interfere with transcription, resulting in either 
activation or repression. Both Cdk9 and FoxO1 are transcriptionally inactive upon 
acetylation and the subsequent accumulation at PML bodies (Kitamura et al., 
2005), but  in the case of FoxO1, acetylation probably precedes and is required for 
the localization at PML bodies since the non acetylable mutant of FoxO1 cannot 
localize at PML bodies.  
PML bodies are not the only transcriptionally repressive compartment where 
acetylated protein can be targeted. The PGC-1a transcription factor is directly 
acetylated by GCN5 resulting in a transcriptionally inactive protein. This proteins 
re-localizes to nuclear foci characterized by the presence of the nuclear co-




Thus even if acetylation (of both histones and transcription factors) generally 
potentiates transcription, Cdk9 is not the first transcription factor to be inhibited by 
acetylation. Acetylation of NF-kB p65 (Kiernan et al., 2003), HMGI(Y) (Munshi et 
al., 2001), IRF7 (Caillaud et al., 2002), AFX (Foxo4) (Fukuoka et al., 2003) Brm 
(Bourachot et al., 2003) and PGC1a (Lerin et al., 2006) turns off transcription, 
which may serve as a feedback mechanism to control the duration of transcription.  
 
What is the functional consequence of Cdk9 acetylation? 
Several reports have suggested that there should be a post-recruitment regulation 
of Cdk9 kinase activity on promoter and coding regions and that simple recruitment 
of P-TEFb does not imply phosphorylation of RNAPII on Ser2.  
In vivo chromatin immunoprecipitation assays demonstrated that, during 
transcription, Cdk9 is present both on promoter and coding regions of different 
genes, however Ser2P/RNAPII increases towards the 3’ of the genes (Ahn et al., 
2004; Boehm et al., 2003; Cho et al., 2001). On the human p21 gene (Gomes et 
al., 2006), low amounts of P-TEFb bind the 5’ part of the coding region also in 
conditions when RNAPII is not phosphorylated on Ser2 (Gomes et al., 2006). 
Additionally, Cdk9 is present in in vitro reconstituted HIV-1 pre-initiation and 
elongation complexes, but RNAPII CTD Ser2 is phosphorylated only in the last 
ones (Isel and Karn, 1999; Marshall et al., 1996; Marshall and Price, 1995; Ping 
and Rana, 1999; Ping and Rana, 2001; Zhou et al., 2001).  
In particular, it seems that, on the HIV-1 promoter, a number of mechanisms 
concentrate high amounts of inactive P-TEFb in close proximity of its substrates, 
ready to be activated. First, an inhibitory intramolecular interaction between the N- 
and C-terminal regions of CyclinT1, which prevents the ternary complex assembly, 
is relieved by the binding of the transcription elongation factor Tat-SF1 to the C-
terminal region in CyclinT1 (Fong and Zhou, 2000). Second, the presence of TFIIH 
in the HIV-1 PIC inhibits Cdk9 phosphorylation and its subsequent kinase activity 
on RNAPII CTD; as TFIIH is released from the elongation complex, Cdk9 
phosphorylation is observed (Zhou et al., 2001). In addition, the ubiquitylation of 




(Barboric et al., 2005). All these mechanisms contribute to ensure a tight control of 
the promoter clearance: RNAPII should be phosphorylated by Cdk9 only after the 
cap is positioned on 5’ of the mRNA in order to avoid wasteful rounds of 
transcription of uncapped mRNAs (Cho et al., 2001).  
Here we found that in conditions of HIV-1 latency, when proviral transcription is 
very low and Ser2P RNAPII is virtually absent from HIV-1 genome, there is a 
certain amount of catalytically inactive, acetylated Cdk9 already bound to the HIV-1 
genome. After TPA-mediated transcription activation,  Cdk9 can be found 
associated with both the promoter and the proviral genome together with  RNAPII 
Ser2P accordingly to literature (Boehm et al., 2003; Bres et al., 2005; Cho et al., 
2001; Gomes et al., 2006), whereas Ac-Cdk9 becomes absent from both regions. 
Taken together, these results suggest that Cdk9 might be recruited onto the 
genome as an acetylated protein, which is then specifically deacetylated (or 
exchanged with not acetylated?) when transcription is activated. Several data 
indicate that the inhibition of Cdk9 kinase activity by flavopiridol or DRB does not 
impair its recruitment onto DNA (Barboric et al., 2001; Gomes et al., 2006; Ni et al., 
2004), so it is conceivable that acetylated Cdk9 can be also recruited to DNA given 
that it can still bind CyclinT1. Since histone acetylation is continually reversed by 
deacetylases in order to  ensure rapid turnover of chromatin acetylation states 
(Topalidou et al., 2003; Yamagoe et al., 2003), this mechanism could be active 
also on non-histone proteins such as  Cdk9. Therefore, finding the specific Cdk9 
deacetylase and the mechanism that controls its activity will help to understand 
also the functional role of Cdk9 acetylation. 
How all these findings fit with the well established notion of P-TEFb being recruited 
on HIV-1 promoter by Tat when transcription is activated? 
Work from other laboratories has shown that P-TEFb is not present on 
transcriptionally silent HIV-1 genome (Bres et al., 2005; Kim et al., 2006) nor is 
recruited when transcription is induced by a mutated Tat protein (C22G) incapable 
of binding P-TEFb (Kim et al., 2006).  
One possible explanation for the differences between these results and ours can 
be ascribed to the cell lines used: Jurkat cells carrying an integrated lentiviral 




control of the integrated HIV-1 LTR for Bres et al. and U1 cells for our experiments. 
U1 cells contain two integrated HIV proviruses, each with mutant tat: one blocked 
by the deletion of a translational initiation codon and the other encoding a form of 
Tat containing histidine to leucine mutation at amino acid 13 (Emiliani et al., 1998). 
This mutation causes a decrease in the transactivation potency of the mutant Tat 
protein, however, it has been shown that higher levels of Tat can compensate for 
the defect (Adams et al., 1994; Emiliani et al., 1998) suggesting that it probably 
retains some ability to bind P-TEFb. In unstimulated conditions, U1 cells are not 
completely silent, but express low levels of short, incomplete HIV-1 transcripts 
reflecting the impaired Tat activity (Adams et al., 1994; Adams et al., 1999). Thus 
we can speculate that this leakiness of transcription regulation can allow the 
recruitment of small amounts of Cdk9 on HIV-1 genome, but not bypass the 
inhibitory effect given by acetylation of Cdk9.  
 
HIV-1 Latency  
In essence, Cdk9 acetylation contributes to the understanding of the molecular 
determinants of HIV-1 latency – an issue of major relevance and overall interest. 
Indeed, the establishment of a latent infection represents the major obstacle to 
HIV-1 eradication. The main  reservoir is composed of latently infected resting 
memory CD4+ T cells that carry an integrated provirus that is transcriptionally silent 
(Chun et al., 1995; Chun et al., 1997).  The  extremely long half-life of these cells, 
combined with a tight control of HIV-1 expression, make this reservoir ideally suited 
to maintain hidden copies of the virus, which are in turn able to trigger a novel 
systemic infection upon discontinuation of therapy. Given the importance of this 
reservoir, a lot of effort has been invested to characterize these cells from infected 
patients and also to understand the molecular determinants that allow the provirus 
to remain silent. Such mechanisms are mostly related to transcriptional control of 
viral expression and thus depend on the chromatin environment at the site of viral 
integration and on the interaction of the viral Tat transactivator with host factors. 
In respect to the second point it is worth mentioning that, in resting T-cells, P-TEFb 




et al., 2001; Herrmann et al., 1998).  Moreover we demonstrated that, when the 
integrated provirus is transcriptionally silent, the low amount of P-TEFb bound to 
the HIV-1 genome is catalytically inactive because acetylated. On the other hand, 
in resting T-cell, general transcription activators such as Sp1 are available to bind 
the HIV-1 LTR, therefore the initiation of transcription is not completely inhibited 
but, in absence of the Tat protein and of an active P-TEFb complex, transcription is 
mostly non-processive. As a matter of fact the presence of short, non-
polyadenylated promoter-proximal transcripts has been directly demonstrated in 
highly purified resting CD4+ T-cells from patients on HAART (Lassen et al., 2004). 
Taken together  these results suggest that, in resting T-cell, there is not an 
absolute block at the level of transcription initiation. Rather there is a relative block, 
with transcriptional initiation occurring with reduced efficacy due to the absence in 
resting cells of crucial host transcription factors and the viral protein Tat. The 
absence of Tat and active P-TEFb is largely manifest at the subsequent step of 
transcriptional elongation and the result is the production of abortive rather than full 
length transcripts. 
In this context it will be interesting to address the relationship between Cdk9 
acetylation and the kinase activity of P-TEFb in cells that are differently susceptible 












DISSECTION OF PROTEIN-PROTEIN INTERACTIONS THAT GOVERN 
HIV-1 TRANSCRIPTION BY BIOPHYSICAL METHODS. 
Introduction 
Tat-associated factors and HIV-1 transcription 
Understanding the molecular mechanisms controlling silencing and reactivation of 
the HIV-1 provirus at its integration site within the host cell genome has profound 
implications for both the elucidation of the HIV disease pathogenesis and for its 
pharmacological control (Cohen and Fauci, 2001; Finzi et al., 1999). Such 
mechanisms are mostly related to transcriptional control of viral gene expression 
and thus depend on the chromatin environment at the site of viral integration and 
on the interaction of the viral Tat transactivator with host factors. Transcriptional 
activation occurs essentially through Tat-mediated modulation of chromatin 
conformation and transcriptional elongation. These processes in fact are regulated 
by different protein complexes assembled by Tat at the 5’ of each viral transcripts.  
In particular through direct interaction with the CyclinT1 protein, Tat recruits the P-
TEFb complex  and therefore promotes hyper-phosphorylation of RNAPII CTD and 
transcriptional processivity. Interestingly the RelA/p65 subunit of NF-kB (Barboric 
et al., 2001) as well as the Sp1 transcription factor (Yedavalli et al., 2003), have 
also been shown to interact with P-TEFb. The recruitment of P-TEFb by these two 
factors might be responsible for the first rounds of HIV-1 transcription that occurs 
prior to the synthesis of Tat. 
In addition to its functional interaction with P-TEFb, Tat associates with different 
factors that possess acetyltransferase activity. These factors include the 
transcriptional co-activators p300 and the highly homologous cyclic adenosine 
monophosphate (cAMP)-responsive binding protein (CREB)-binding protein (CBP) 
(Marzio et al., 1998), the p300/CBP-associated factor (P/CAF) (Benkirane et al., 
1998), the general control nonderepressible-5 (GCN5) factor (Col et al., 2001), the 
TIP60 protein (Kamine et al., 1996), and the general transcription factor TAFII250 
(Weissman et al., 1998). Chromatin immunoprecipitation experiments at the HIV-1 




H3 and H4 histones in this region, which precedes the actual onset of transcription. 
Histone acetylation is paralleled by the recruitment of specific acetyltransferases to 
the promoter, which is cell-type specific and depends on the stimulus used for 
transcriptional activation (Lusic et al., 2003). Finally, it is of interest that, besides 
histones, Tat itself is a substrate for acetylation by p300/CBP, P/CAF, and GCN5 
(Col et al., 2001; Deng et al., 2000; Kiernan et al., 1999; Ott et al., 1999). Tat is 
acetylated by P/CAF on Lys28 and by p300 and hGCN5 on Lys50. The acetylation 
of Tat has been proposed to regulate two discrete and functionally critical steps in 
transcription, binding to P-TEFb and release of Tat from TAR RNA (Bres et al., 
2002; Dorr et al., 2002; Kaehlcke et al., 2003). 
Since cellular factors play a critical role in  HIV-1 transcription, it is conceivable that 
HIV-1 gene expression undergoes the same controls as cellular gene expression. 
In particular the transient assembly and disassembly of multi-protein complexes 
involved in nuclear processes, such as transcription, in mammalian cells appear to 
be highly ordered and spatially defined processes. 
For example, it has becoming widely accepted that genes whose proteins work 
together, and therefore needs to be co-expressed, are transcribed in the same 
“transcription factory” within the nucleus (Osborne et al., 2004). 
An approach to the understanding of the spatial regulation of HIV transcription is 
the visualization of the subnuclear dynamics of the proteins involved in this process 
and the study of their reciprocal interactions. These two issues can now be tackled 
on a submicrometric scale, by the exploitation of high-resolution optical 
spectroscopy approaches for the visualization of proteins labeled with fluorescent 
tags. Most of these recent techniques rely on the properties of the green 
fluorescent protein (GFP) from the jellyfish A. victoria (Tsien, 1998). Variants of this 
autofluorescent protein are continually being engineered with improved optical 
properties that are exploited in a variety of techniques (Lippincott-Schwartz et al., 
2001; Nagai et al., 2002). In particular, protein–protein interactions can be 
visualized in a single cell by fluorescence resonant energy transfer (FRET) (Day et 





Fluorescence Resonance Energy Transfer (FRET) 
FRET is a physical phenomenon in which energy absorbed by a fluorophore is 
transferred to another molecule through a nonradiactive pathway. For resonance 
energy transfer to occur, two specific conditions must be met. (i) The emission 
spectrum of the fluorophore, also called the donor, must overlap the acceptor 
molecule’s absorbance spectrum. (ii) Donor and acceptor molecules must reside 
within 10 nm (100 Å) of each other.  
 
Figure 33. EGFP and EBFP spectra.  
 
Among the fluorophore, pairs with spectral characteristics optimal for FRET are 
those formed by some variants of the green fluorescent proteins (GFP), namely the 
CFP (cyan)/YFP (yellow) and the BFP (blue)/EGFP (green) pairs. Technically, the 
visualization of fluorescence from ECFP/EYFP is easier, due to the higher temporal 
stability of the photon emission associated to the reduction of photobleaching 
effects. However, the determination of FRET efficiency between these two proteins 
requires careful measurement due to the extensive overlapping of their emission 
spectra (Bastiaens and Pepperkok, 2000; Lippincott-Schwartz et al., 2001). In 
contrast, the emission of BFP and EGFP overlaps only minimally. Thus, the FRET 




acceptor excited within its absorption band and at resonance with the donor 
absorption (Marcello et al., 2001). Visualization of BFP-tagged proteins, however, 
is difficult when compared to other GFP-fusion proteins as the BFP rapidly converts 
to a dark (non-emissive) state after photoexcitation. 
Förster showed that the efficiency of resonance energy transfer, or FRET efficiency 
(the fraction of the photon energy absorbed by a fluorescent molecule that is 
transferred to an acceptor through dipole-dipole interactions), has a sixth power 
dependence on the separation distance between the donor and the acceptor. It is 
this strong dependence on separation distance that allows FRET imaging to be 
used to study molecular interactions on a 1- to 10-nm scale. For the green 
fluorescent protein (GFP):blue fluorescent protein (BFP) pair,  the Förster radius 
(the distances at which FRET efficiency is 50%) is less then 4 nm; this implies that 
simple co-localization of two proteins is not sufficient to yield energy transfer (Heim 
and Tsien, 1996; Selvin, 2000; Tsien and Miyawaki, 1998). 
FRET presents several advantages in comparison with other techniques employed 
to detect protein–protein interactions. Firstly, the presence of FRET actually 
indicates protein–protein interaction at distances of a few nanometers for many 
pairs of optically matched fluorophores. Secondly, the use of gene-encoded GFP 
variants allows the visualization of interactions in real time and in living cells 
(Janetopoulos and Devreotes, 2002; Jiang and Sorkin, 2002; Majoul et al., 2001; 
Mayr et al., 2001). Thus, the physiological conditions of the experiments can be 
varied in order to assess whether the formation of a specific protein complex is 
influenced by external stimuli. Thirdly, FRET actually determines not only ‘‘if’’ but 
also ‘‘where’’ proteins interact inside the nucleus (Jiang and Sorkin, 2002; Marcello 
et al., 2001). This is of particular value, especially given the increasing importance 




Intramolecular FRET can be measured when both the GFP donor and the acceptor 
are fused to the same host molecule and it allows to detect dynamic conformational 




been developed to measure several ions, cyclin nucleotides, metabolites, 
neurotransmitters, the balance between protein kinases and phosphatases 
activities, and activities of proteases, small G proteins, and histone 
acetyltransferases. 
 
Figure 34. FRET sensor (indirect). A substrate undergoes modification (1) (e.g. 
phosphorylation, orange dot), causing a conformational change (2) and altering 
FRET from CFP to YFP. 
 
One of the first demonstration of this technique was performed by Mitra et al. (Mitra 
et al., 1996) who fused a BFP and GFP in the same molecule, separated by a 
flexible polypeptide linker  containing a factor Xa protease cleavage site. When 
incubated with factor Xa, cleavage of the linker was followed by a decrease in 
FRET.  
One example of FRET-based calcium biosensor are “camaleons” which consist of 
a tandem fusion of CFP, Ca2+-calmodulin (CaM), M13 peptide and YFP. Upon an 
increase in Ca2+ concentration, the CaM component of the hybrid protein binds 
Ca2+ and preferentially wraps around the fused M13 peptide. This conformational 
change results in a decrease in the distance between the two GFP variants, and 
therefore an increase of FRET (Miyawaki et al., 1997). 
 
Intermolecular FRET 
Intermolecular FRET can occur when the GFP donor and the acceptor are on 
different macromolecules. In these conditions FRET can detect dynamic protein-
protein interaction in live cells, provided that the fluorescent proteins get within 6-8 
nm of each other. Recently, the possibility of using three fluorescent proteins to 
study higher order complexes has been addressed by adding a monomeric red 




FRET donor for YFP; subsequently, YFP can act as a FRET donor for mRFP. 3-
FRET has been shown in multiprotein complexes and in protein trimerization 
(Galperin et al., 2004; He et al., 2005).  
 
Figure 35. Intermolecular FRET/ 3-FRET. Binding of X to Y (1) leads to CFP-YFP 
FRET. Additional binding of Z (2) makes RFP an acceptor for X/Y. 
 
An early example of GFP-based intermolecular FRET occurred with Bcl-2 and Bax, 
which play a crucial role in apoptosis, as well as in the indication and progression 
of human cancer. A direct interaction in the mitochondria between Bcl-2 and Bax 
was shown when a GFP fused to the N-terminus of Bcl-2 and a BFP fused at the 
N-terminus of Bax were co-expressed in the same cell (Rampino et al., 1997; Yin 
et al., 1997).  
FRET has now become one of the preferred methods for studying protein-protein 
interactions and validate structural details revealed by x-ray crystallography and 
electron microscopy in living cells. Not surprisingly, the number of PubMed-listed 
citations using FRET has increased 10-fold over the past 10 years (Vogel et al., 
2006).  
We have therefore exploited the application of high-resolution confocal microscopy 
and FRET analysis to study the subcellular localization and structural conformation 
of different proteins involved in HIV transcription and their reciprocal interactions. 
 
How Is FRET measured? 
Numerous methods have been used for measuring FRET (Jares-Erijman and 
Jovin, 2003; Sekar and Periasamy, 2003). FRET methods can be divided into four 
fundamental categories: (i) methods that monitor changes in donor fluorescence; 




simultaneously measure changes in both donor and acceptor fluorescence using 
spectral imaging; and (iv) methods that monitor changes in the orientation of the 
fluorophores. 
The most popular methods used for measuring FRET involve monitoring acceptor 
emission as a result of donor excitation (Gordon et al., 1998). This technique is 
commonly referred to as the three-cube method because it involves acquiring three 
different images using three fluorescent filter sets. First, a FRET image is 
generated by using a filter set that excites the donor but measures emission from 
the acceptor. Images obtained with filter sets that measure emission from donors 
or acceptors when directly excited are then used to correct the “FRET image.” 
These corrections are required because the emission of the donor can bleed 
through into the FRET image and because excitation wavelengths that are used to 




Materials and Methods 
Plasmids 
EGFP-Cdk9 and Cdk9-EGFP  were obtained by PCR amplification of Cdk9 from 
pcDNA3-Cdk9-his and  cloning as an EcoRI/BamHI fragment into pEGFP-C1 and 
pEGFP-N1 respectively (Clontech). 
pcDNA3-Tat-EBFP, pcDNA3-EGFP-CyclinT1 and pEGFP-PML-IV were kindly 
provided by A. Marcello (Trieste) (Marcello et al., 2001; Marcello et al., 2003). 
The plasmid pCycT300-EGFP, carrying EGFP at the 3’ end, was obtained by PCR 
amplification of the N terminus of CyclinT1 and cloning as an EcoRI/BamHI 
fragment into pEGFP-N1 (Clontech).  
The plasmid pBFP-CycT300-EGFP, carrying BFP at the 5’-end and GFP at the 3’-
end, was obtained by PCR amplification of the previous construct pCycT300-EGFP 
and cloning as a HindIII/SalI fragment into pBFPC1 (Clontech).  
pGEX-P/CAF(Y760D) and pGEX-P/CAF(Y761D) were obtained by PCR 
mutagenesis from the template pGEX-P/CAF, kindly provided by M. Benkirane 
(Montpellier, France). EGFP-tagged derivatives were obtained by subcloning the 
EcoRI/XhoI fragment from the pGEX constructs into the EcoRI/SalI sites of 
pEGFP-C2 (Clontech).  
 
FRET 
In the experiments described in this thesis, we transfected epithelial cells (HL3T1) 
by the calcium phosphate method with the various expression plasmids fused to 
the optically-matched fluorescent tags in four-chambers of glass slides. After 48 h 
we fixed cells in 4% paraformaldehyde and mounted them in 70% glycerol for 
FRET analysis.  
FRET analysis was performed in two steps. Firstly, enhanced green fluorescent 
protein (EGFP) emission was collected by integrating the fluorescence signal 
around 520 nm (bandwidth 40 nm) under direct EGFP excitation at 480 nm 
(wavelength selection was obtained by 40 nm band-pass filters, excitation power 
was 5 W/cm2). Secondly, EGFP emission in the same frequency range was 




bandwidth 60 nm). Background was detected out of the cell under study for each 
frame and subtracted from the relevant fluorescent signal. Following this 
procedure, the ratio between the two measured EGFP emissions (data taken 
following excitation at 350 nm divided by those at 480 nm) provides the FRET 
signal. Fluorescence was collected by a PentaMax 512-EFT intensified CCD 
camera with detection times of the order of 0.1 s (in particular, for data taken under 
excitation at 350 nm they were five times longer than for those relative to 480 nm 
excitation). Data acquisition and analysis were performed with the Metamorph 
software from Universal Imaging Corporation, a subsidiary of Molecular Devices. 
When evaluating FRET ratios, emission intensities were scaled to take into account 





Results and Discussion 
Cdk9 directly interacts with PML, but not with Tat 
CyclinT1, the main Cdk9 partner, has been initially discovered as a cofactor of the 
human immunodeficiency virus type 1 (HIV-1) Tat transactivator (Wei et al., 1998).  
Previous studies from the laboratory exploited high resolution fluorescence 
resonance energy transfer (FRET) to visualize and quantitatively analyze the direct 
interaction between Tat and CyclinT1 inside the cells (Figure 36). They found that 
CyclinT1 resides in specific subnuclear foci which are in close contact with nuclear 
speckles and that Tat determines its redistribution outside of these compartments. 
Consistent with this observation, strong FRET was observed between the two 
proteins both in the cytoplasm and in regions of the nucleus outside of CyclinT1 
foci and overlapping with Tat localization (Marcello et al., 2001).  
 




The subnuclear foci in which CyclinT1 resides are coincident with promyelocytic 
leukaemia (PML) bodies (Marcello et al., 2003) and FRET experiments proved that 
CyclinT1 physically interacts in vivo with the PML protein within these 
compartments. Whereas Tat expression determines CyclinT1 redistribution outside 
of these compartments and promotes transcriptional activation (Marcello et al., 
2001), CyclinT1 or PML overexpression forces CyclinT1 and also Tat in nuclear 
bodies and correlates with an inhibition of transcription (Marcello et al., 2003).  
In light of our new data on the relationship between Cdk9 and PML, we decided to 
further extend the FRET analysis at this couple of proteins.  
Therefore we co-transfected cells with EGFP-Cdk9 and EBFP-PML-IV. Panels in 
row b of Figure 37A show the intracellular distribution of fluorescence at 520 nm 
(the peak wavelength of EGFP emission) under excitation at 480 nm. In these 
conditions, most cells transfected with EGFP-Cdk9:EBFP-PML-IV showed the 
characteristic pattern already observed in other experiments and consisting of large 
nuclear foci of PML-IV and Cdk9. FRET analysis was performed by comparing 
EGFP emission at 520 nm, following EBFP excitation at 350 nm (Figure 37A, 
panels in row c), with that following excitation at 480 nm of the same cells (Figure 
37A, panels in row b). In these conditions, samples expressing both EGFP-Cdk9 
and EBFP-PML-IV scored positive for FRET, indicating direct interaction between 
the two proteins. The detailed, quantitative analysis of at least 10 cells expressing 
each of the analyzed protein pairs is presented in Figure 37B, showing the 
percentile distribution of FRET values. FRET between PML and Cdk9, is not 
restricted to nuclear bodies but also occurs in the nucleoplasm. This is in 
agreement with previous data about the interaction between Cyclin T1 and PML, 
which showed positive FRET values in both compartments (Marcello et al., 2003).  
In contrast,  no FRET signal was obtained between Cdk9 and Tat even if we tried 
three different couples of tagged protein: EGFP-Cdk9:Tat-EBFP, Cdk9-EGFP:Tat-
EBFP and EBFP-Cdk9:Tat-EGFP (figure A, columns 1, 2, 3). This result  is in 
accord with literature data reporting the interaction between CyclinT1, and not 










A structural model of the N-terminus of CyclinT1  
Cyclin T1 can be grossly sub-divided into two major domains. The N terminus of 
the protein (aa 1–300) shares partial homology with other members of the Cyclin T 
family (cyclin box) (Wei et al., 1998). It contains the Tat recognition motif (TRM) 
that includes a critical cysteine residue at position 261 present in human CyclinT1, 
but absent in its rodent homologue (Bieniasz et al., 1998; Garber et al., 1998). The 
N-terminus domain of CyclinT1 is also important for the protein–protein 
associations with Cdk9, NF-kB, CIITA and c-Myc (Barboric et al., 2001; Eberhardy 
and Farnham, 2001; Kanazawa et al., 2000). The C-terminus of CyclinT1 is less 
characterized and contains a putative coiled-coil region (aa 379–430); a histidine-
rich domain (aa 506–530) and a carboxy-terminus PEST sequence (aa 700–726). 
The C-terminus of CyclinT1 is involved in the association with the RNAPII CTD 
(Fong and Zhou, 2000; Taube et al., 2002) and the PML protein (Marcello et al., 
2003).  
At present, no three-dimensional structure of Cyclin T1 is available. Therefore,  in 
collaboration with the Physics Laboratory of Scuola Normale Superiore (F. Beltram, 
A. Ferrari) and the International School for Advanced Studies (ISAS) and INFM-
DEMOCRITOS Modeling Center for Research in Atomistic Simulation in Trieste (P. 
Carloni, S. Pantano), we have used bioinformatics tools to model the N-terminus 
(aa 27–263) of CyclinT1, that is the region responsible for binding to Cdk9 and Tat.   
Since the cyclin box is highly conserved among cyclins,  we build a structural 
model of CyclinT1 based on the X-ray structure of Cyclin H, another member of the 
cyclin family involved in transcription, whose X-ray structure was available.  This 
model suggested that the N- and C- termini parts of the CyclinT1 cyclin box should 
be in close proximity. Therefore  we took advantage of the complex interactions 
between the HIV-1 Tat protein and CyclinT1 in vivo to validate this prediction. 
Specifically, we estimated the distance between the N and C termini of the cyclin 
box by measuring the fluorescence resonance energy transfer (FRET) between 
fluorescent proteins genetically fused to the N- and C-termini of CyclinT1 cyclin box 
and to the C-termini of Tat in living cells. 
As a first attempt, we tried and provide an estimation of this proximity by intra-




tagged at the N-terminus with the BFP and at the C-terminus with EGFP. FRET 
image analysis of individually transfected cells are shown in Figure 38A, column 3. 
FRET analysis was performed by comparing EGFP emission at 520 nm (the peak 
wavelength of EGFP emission), following BFP excitation at 350 nm (Figure 38A, 
panels in row c), with that following excitation at 480 nm of the same cells (Figure 
38A, panels in row b). As it can be seen from Figure 38, in this case no FRET 
signal was obtained. 
We then proceed to investigate this proximity by intermolecular FRET, taking 
advantage of the fact the CyclinT1 TRM is located around position 261, 
immediately after the cyclin box. We therefore co-transfected human HL3T1 cells 
with plasmids expressing CyclinT1, tagged at the N-termini with EGFP, and Tat 
tagged at the C-termini with BFP. Most cells transfected with EGFP-CyclinT1:Tat-
BFP (Figure 38, panel b1) showed the characteristic nuclear punctuated pattern of 
CyclinT1 (Herrmann and Mancini, 2001; Marcello et al., 2001). Samples expressing 
both EGFP-CyclinT1 and Tat-BFP scored positive for FRET. This suggests that the 
distance between the N-terminus of Cyclin T1 (where is EGFP) and the TRM 
region (where Tat binds) is small enough for FRET to occur. Based on these 
findings, we tested whether fusing GFP at the C terminus of CyclinT1 cyclin box 
provides FRET with Tat-BFP. Cells transfected with CycT300-EGFP:Tat-BFP 
(Figure 38, column 2) showed a nucleo-cytoplasmic distribution of CycT300-EGFP 
at 520 nm under excitation at 480 nm. The difference of distribution of the protein 
with respect to the wild-type CyclinT1 reflected the lack of the carboxy-terminal 
domain of the protein, which was responsible for the punctuated nuclear 
localization through binding to the PML protein (Marcello et al., 2003). EGFP 
emission at 520 nm, following BFP excitation at 350 nm, scored positive for FRET, 
substantiating the fact that Tat-BFP was within 4 nm to the N and C termini of 
CycT1(1 – 300). The detailed, quantitative analysis of at least 10 cells expressing 
for the protein pairs is presented in Figure 38B, showing the percentile distribution 
of FRET values. We consider the signal from cells transfected with EGFP and BFP 










Thus, by measuring FRET between EGFP-CycT1:Tat-BFP and CycT1-EGFP:Tat-
BFP complexes we are able to confirm spatial proximity of the N- and C-terminus 
of cyclin box of CyclinT1  in living cells. 
In conclusion, the model presented here is consistent with all experimental data up 
to the best of our knowledge. However, it must be kept in mind that it suffers the 
obvious limitations and uncertainties of comparative modeling, particularly at low 
sequence identity levels. Still, we believe that it may be useful to test working ideas 
and inspire new biochemical experiments aimed to clarify structural features of 




Insights into HIV-1 Tat:P/CAF bromodomain interaction 
Besides histones, Tat itself is a substrate for acetylation by p300/CBP, P/CAF, and 
GCN5 (Col et al., 2001; Deng et al., 2000; Kiernan et al., 1999; Ott et al., 1999).  
P/CAF was able to bind to the cysteine-rich region of non-acetylated Tat and 
acetylated Lys28 within the transcription activation domain of Tat. This post-
translational modification abrogated the interaction between P/CAF and Tat, but 
significantly enhanced the recruitment of P-TEFb by Tat (Bres et al., 2002; Kiernan 
et al., 1999). The acetylation site of p300/CBP, as well as hGCN5, has been 
mapped to Lys50 (and, weakly, to Lys51), a highly conserved amino acid within the 
TAR RNA-binding domain of Tat. This second post-translational modification leads 
to the dissociation of P-TEFb-Tat from TAR RNA and subsequent binding to the 
elongating RNAPII (Col et al., 2001; Kaehlcke et al., 2003; Kiernan et al., 1999; Ott 
et al., 1999). In addition, acetylation of Tat on Lys50 by p300/CBP also served as a 
signal for the bromodomain of P/CAF to recruit this transcriptional co-activator to 
the elongating RNAPII. This results in the formation of a P-TEFb-Tat-P/CAF ternary 
complex associated with the elongation complex during transcriptional elongation 
(Bres et al., 2002; Dorr et al., 2002; Kiernan et al., 1999; Mujtaba et al., 2002).  
Structural insights into the binding mode of P/CAF to Lys50 acetylated Tat were 
provided by determination of the NMR structure of the peptide 
SYGRAcK50KRRQRC (that corresponds to the Tat residues 46 to 55, with an 
acetyl group on lysine 50) in complex with the acetyllysine (AcK)-binding domain of 
P/CAF (Mujtaba et al., 2002). P/CAF consists essentially of two domains, a 
catalytic domain with histone acetyltransferase activity, which does not play any 
role in Tat binding, and an acetyllysine-binding domain, termed the bromodomain 
(BD). The relatively small association constant estimated for the P/CAF BD:AcK50 
Tat peptide complex suggests that important interactions may arise by additional 
contacts present only in the full-length Tat protein.  
Therefore, starting from this BD/peptide structure, we used molecular dynamics 
simulation techniques to construct a model of the full-length AcK50 Tat:P/CAF BD 
interaction  and then we provide a functional validation of this model inside the 




The model predicted  that, in addition to most of the interface contacts found in the 
NMR structure, a large part of the protein–protein interaction surface is formed by 
hydrophobic contacts between the core domain of Tat and one loop of P/CAF. In 
particular, two tyrosine residues of P/CAF are predicted to play a crucial role in Tat 
binding: Y760, which interacts with AcK50 Tat, and Y761, which forms hydrophobic 
contacts with the Tat core domain.  
To experimentally ascertain the relevance of Tyr760 and Tyr761 in maintaining the 
interaction between AcK50Tat and P/CAF, we selectively mutated them to 
aspartate, since the calculations data suggested that the change from a 
hydrophobic to a hydrophilic amino acid should affect the interaction of the protein 
with the hydrophobic core of Tat. 
 
 
Figure 39. Functional characterization of the P/CAF mutants 
 
Functional characterization of the P/CAF mutants 
Wild-type P/CAF and the P/CAF mutants Y760D and Y761D were obtained as 
recombinant proteins fused to GST, and their enzymatic activity was tested. As 
shown in Figure 39A, both the wild-type protein and the two mutants, but not 
unfused GST, were able to acetylate histones, and, in particular, H3. In addition, all 




clearly indicate that the Y760D and Y761D mutations do not impair the enzymatic 
activity of P/CAF. Next, expression vectors were obtained for the two mutants, as 
well as for the wild-type P/CAF, in which the proteins had EGFP fused at their N-
terminus. Wild-type EGFP-P/CAF and the two mutants were co-transfected in 
HeLa cells together with an expression vector for Tat and an LTR-Luciferase 
reporter. In the presence of suboptimal concentrations of Tat, the HIV-1 promoter 
was clearly co-activated by wild type P/CAF but not by either of the two mutants 
(Figure 39C). 
 
Visualization of in vivo interaction between P/CAF and Tat by FRET 
The lack of functional co-activation of Tat-mediated transcription by the two P/CAF 
mutants is consistent with the possibility that the two mutations impair binding of 
the two proteins, either by disrupting the hydrophobic pocket that homes AcK50 
(Y760D) or by hindering contacts between the BD and the Tat core (Y761D). 
Therefore, we set out to directly visualize the binding between Tat and P/CAF 
inside the cells by FRET using the two proteins tagged with the BFP:EGFP 
fluorescent protein pair. FRET experiments between P/CAF and Tat were 
performed by transfection of HeLa cells with plasmids expressing EGFP fused at 
the C-terminus of wild-type P/CAF or the P/CAF mutants together with Tat-BFP, 
followed by the analysis of fluorescence at 520 nm (the peak wavelength of EGFP 
emission). Representative results of these experiments are shown in Figure 40A. 
The panels in row b show the intracellular distribution of fluorescence at 520 nm 
under excitation at 480 nm, characteristic of EGFP. FRET analysis was performed 
by comparing acceptor EGFP emission at 520 nm, following donor BFP excitation 
at 350 nm (Figure 40A, panels in row c), with that following excitation at 480 nm of 
the same cells (Figure 40A, panels in row b). In these conditions, the samples 
expressing both EGFP-P/CAF wild-type and Tat-BFP scored positive for FRET, 
indicating direct interaction between the two proteins. In contrast, no FRET was 
observed between Tat and the nucleolar protein fibrillarin, despite the localization 
of the latter protein in the same compartments as Tat. We can therefore conclude 
that P/CAF and Tat directly interact within the nucleus of co-transfected cells. Next 




Y761D completely abolished the FRET signal (Figure 40A), indicating that the two 
proteins were no longer at a distance favorable for FRET. The detailed, quantitative 
analysis of at least 10 expressing cells for each of the analyzed protein pairs is 
presented in Figure 40B, showing the percentile distribution of FRET values. 
 
Figure 40. Visualization of in vivo interaction between P/CAF and Tat by FRET. 
 
In conclusion the two P/CAF BD mutants at Tyr760 and Tyr761 are both impaired 




these two amino acids are essential to maintain the contacts between Tat 
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